<SEC-DOCUMENT>0001140361-23-008076.txt : 20230222
<SEC-HEADER>0001140361-23-008076.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222172907
ACCESSION NUMBER:		0001140361-23-008076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230220
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		23654742

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10048628_form8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:erna="http://eternatx.com/20230220" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_25044cef1f56455e9578189b3aab123e" contextRef="c20230220to20230220" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_0458c2ed6e6840d7ae8396e06eb93d45" contextRef="c20230220to20230220">0000748592</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_86f951afb78c444b86079efd2ccf8734" contextRef="c20230220to20230220">10531 4S COMMONS DRIVE</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_d8c25c8fcc084b0582604d96e1ec64d0" contextRef="c20230220to20230220">SUITE 166-550</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_e6278cb7aa0243eb93f119f7f0d167ca" contextRef="c20230220to20230220">SAN DIEGO</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_16c491966e0d449c8689f3e36f86b228" contextRef="c20230220to20230220">CA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_fcf56aabc71a49178f7e9341812b09e6" contextRef="c20230220to20230220">92127</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20230220.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230220to20230220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-20</xbrli:startDate><xbrli:endDate>2023-02-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div class="BRPFPageHeader" style="width: 100%;"></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;"><a id="z_Hlk104309906"></a><span style="font-size: 14pt;">UNITED STATES</span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_52c60337ab5e4a4f86427b509dac6c3e" contextRef="c20230220to20230220">8-K</ix:nonNumeric></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_3b33c81a345846b681d417c9ec26382d" contextRef="c20230220to20230220" format="ixt:date-monthname-day-year-en">February 20, 2023</ix:nonNumeric></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_af5a345f321c4f55a34abd8e3991156b" contextRef="c20230220to20230220">Eterna Therapeutics Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;"> <span style="font-size: 10pt;"><br />
      </span></div>

  </div>

  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_3c23910a780f4b518dd71a121ab3f547" contextRef="c20230220to20230220" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td colspan="3" style="width: 33.68%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_26f65c3179fe41a09af7afd50ac96c68" contextRef="c20230220to20230220">001-11460</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.72%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_143bd59d435c4575afdcdaeb2b4ed962" contextRef="c20230220to20230220">31-1103425</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td colspan="3" style="width: 33.68%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Commission File Number)</div>
          </td>

    <td style="width: 33.72%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(IRS Employer Identification No.)</div>
          </td>

  </tr>

  <tr>

    <td colspan="2" style="width: 49.01%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="width: 49%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td colspan="2" style="width: 49.01%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="-sec-ix-hidden:Fact_86f951afb78c444b86079efd2ccf8734">1035 Cambridge Street</span>, <span style="-sec-ix-hidden:Fact_d8c25c8fcc084b0582604d96e1ec64d0">Suite 18A</span></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td colspan="2" style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

  </tr>

  <tr>

    <td colspan="2" style="width: 49.01%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="-sec-ix-hidden:Fact_e6278cb7aa0243eb93f119f7f0d167ca">Cambridge</span>, <span style="-sec-ix-hidden:Fact_16c491966e0d449c8689f3e36f86b228">MA</span></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td colspan="2" style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="-sec-ix-hidden:Fact_fcf56aabc71a49178f7e9341812b09e6">02141</span><br />
            </div>
          </td>

  </tr>

  <tr>

    <td colspan="2" style="width: 49.01%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td colspan="2" style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Zip Code)</div>
          </td>

  </tr>


</table>
  </div>

  <div style="font-size: 10pt;"><br />
  </div>

  <div style="font-size: 10pt;">
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code:&#160;<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_c6c63efb39b542549a4e8522e86ee033" contextRef="c20230220to20230220">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_533083fa238448f1873c0a4dae4ddb48" contextRef="c20230220to20230220">582-1199</ix:nonNumeric></span></div>

  </div>

  <div style="font-size: 10pt;"><br />
  </div>

  <div style="font-size: 10pt;">
    <div style="text-align: justify; font-family: 'Times New Roman';">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

  </div>

  <div style="font-size: 10pt;"><br />
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_5dcb4438ac0c49eeb9cd342c7eb6cff5" contextRef="c20230220to20230220" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="vertical-align: top; width: auto; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2be114314a874ca6867aa1f784dc34a7" contextRef="c20230220to20230220" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="vertical-align: top; width: auto; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_efa4b15ea50549a0822b56244fc35df3" contextRef="c20230220to20230220" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="vertical-align: top; width: auto; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
  </div>

  <div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_c83de09426674aa0b34095ffed9071bc" contextRef="c20230220to20230220" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="vertical-align: top; width: auto; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
  </div>

  <div style="font-size: 10pt;"><br />
  </div>

  <div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 0.96%; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td style="width: 18.76%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Trading symbol</div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td style="width: 36.98%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_9340d16c8e8b4392bd2bd6f33b18feb4" contextRef="c20230220to20230220">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 0.96%; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td style="width: 18.76%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_621e6a01ca6c45a1aae35dbd2a3e7ef2" contextRef="c20230220to20230220">ERNA</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
          </td>

    <td style="width: 36.98%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">The <ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_7d6d984c12114c35b0c14db2d6093a02" contextRef="c20230220to20230220" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
      Act of 1934:</div>

    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_e708b419a44d4721a800fd2ed4a6c5c3" contextRef="c20230220to20230220" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</span></div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
<div><span style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> <br />
      </span></div>

      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;"></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On February 20, 2023, <span style="font-family: 'Times New Roman';">Eterna Therapeutics Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;),


          </span>entered into an exclusive license agreement (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Exclusive License Agreement</span></span>&#8221;) with Factor Bioscience Limited (&#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Factor</span></span>&#8221;),


          pursuant to which Factor has granted to the Company an exclusive, sublicensable, worldwide license under certain patents owned by Factor (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Factor Patents</span></span>&#8221;) for the purpose of, among
          other things, identifying and pursuing certain opportunities to develop products in respect of the Factor Patents and otherwise grant to third parties sublicenses to the Factor Patents.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The term of the Exclusive License Agreement expires on November 22, 2027 (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Expiration


              Date</span></span>&#8221;), but will be automatically extended for an additional two and a half years (such period, the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Renewal Term</span></span>&#8221;) if the Company receives at least $100 million in fees
          from sublicenses to the Factor Patents (&#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Sublicense Fees</span></span>&#8221;) granted by it pursuant to the Exclusive License Agreement. Pursuant to the Exclusive License Agreement, the Company will pay
          Factor 20% of any Sublicense Fees received by the Company before the Expiration Date and 30% of any Sublicense Fees received by the Company during the Renewal Term. The Company may terminate the Exclusive License Agreement upon 120 days&#8217; written
          notice to Factor, and both parties otherwise have additional customary termination rights, including in connection with certain uncured material breaches of the Exclusive License Agreement and specified bankruptcy events.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Matthew Angel, the Company&#8217;s President and Chief Executive Officer, is the co-founder, President, CEO, and a director of
          Factor Bioscience Inc., which is the parent of Factor.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Exclusive License Agreement is only a summary and is qualified in its entirety by reference to
          the full text of the Exclusive License Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01.</div>

        <div style="font-size: 10pt;">&#160;</div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Termination of a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As previously reported, on November 22, 2022, the Company entered into a First Amendment to that certain exclusive license
          agreement, dated as of April 26, 2021 (as amended, the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Amended Factor License Agreement</span></span>&#8221;), by and among Eterna Therapeutics LLC (f/k/a <span style="font-family: 'Times New Roman';">Brooklyn


            ImmunoTherapeutics LLC)</span>, a wholly owned subsidiary of the Company (&#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Eterna LLC</span></span>&#8221;), Novellus Therapeutics Limited, a wholly owned subsidiary of the Company, and Factor.&#160;&#160;
          Effective on February 20, 2023, the Exclusive License Agreement terminated and superseded the Amended Factor License Agreement.&#160; A description of the material terms of the Amended Factor License Agreement is contained in Item 1.01 to the
          Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 22, 2022, which description is incorporated by reference in this Item 1.02.</div>

        <div style="font-size: 10pt;"><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

      <div style="font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12.36%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="border-bottom: 0.75pt solid black;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Exhibit<span style="font-family: 'Times New Roman';"><br />
                  </span>Number</div>
              </div>
            </td>

    <td style="width: 87.64%; vertical-align: top; border-bottom: 2px solid #000000;">
              <div style="border-bottom: 0.75pt solid black;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
                  </span><span style="font-size: 10pt;">Description</span></div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 12.36%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><a href="brhc10048628_ex10-1.htm">10.1*</a></div>
            </td>

    <td style="width: 87.64%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Exclusive License Agreement, dated February 20, 2023, by and between Factor Bioscience Limited and Eterna Therapeutics Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12.36%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12.36%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';">104</div>
            </td>

    <td style="width: 87.64%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> <br />
        </span></div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">*</span><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Pursuant to Item
            601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such
            exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.</span></span></div>

      <div style="font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;"></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
        duly authorized.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td colspan="3" style="width: 50.28%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps;">Eterna Therapeutics Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td colspan="3" style="width: 50.28%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Dated: February 22<span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, 2023</span></div>
            </td>

    <td style="width: 3.82%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>

    <td style="width: 45.44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">/s/ Andrew Jackson</div>
            </td>

    <td style="width: 1.01%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3.82%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 45.44%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Chief Financial Officer</div>
            </td>

    <td style="width: 1.01%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3.82%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">&#160;</div>
            </td>

    <td colspan="2" style="width: 46.45%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br />
      </div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      <div><br />
      </div>

      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div><span style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> </span></div>
</div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10048628_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;">
  </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Hlk126324903"></a><a name="z_Hlk127453951"></a>Exhibit 10.1</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>EXCLUSIVE LICENSE AGREEMENT</u></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS EXCLUSIVE LICENSE AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Agreement</u></font>&#8221;)
        is entered into as of this February 20, 2023 (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effective Date</u></font>&#8221;), by and between Factor Bioscience Limited, a company organized and existing under the laws
        of Ireland (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensor</u></font>&#8221;), and Eterna Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee</u></font>&#8221;). Licensor and Licensee may each be referred to in this Agreement individually as a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Party</u></font>&#8221; and collectively as the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Parties</u></font>.&#8221;</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Licensor and Eterna Therapeutics LLC (f/k/a Brooklyn Immunotherapeutics LLC) (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Brooklyn</u></font>&#8221;), an Affiliate of Licensee, previously entered into an Exclusive License Agreement, by and among Licensor, Brooklyn and Novellus Therapeutics Limited (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Novellus</u></font>&#8221;), as of April 26, 2021, as amended by that certain First Amendment to Exclusive License Agreement, by and among Licensor, Licensee, Brooklyn and Novellus, dated as of
        November 22, 2022 (as amended, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Prior Agreement</u></font>&#8221;);<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>and</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Parties mutually agree to hereby terminate the Prior Agreement in its entirety, and enter into this Agreement, pursuant to
        which Licensor shall grant Licensee rights to certain Licensed Patents in the Field in the Territory (as such terms are defined herein).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the
        receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 1</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Definitions</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, will have the
        following meanings:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Affiliate</u></font>&#8221; means, with respect to a Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the
            purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct
            or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise. For the purposes of this definition and this
            Agreement, and for the avoidance of doubt, (a) Factor Bioscience Limited, Factor Bioscience Pty Ltd, Factor Bioscience LLC, and Factor Bioscience Inc. (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Factor Bio Entities</u></font>&#8221;) are each deemed not to be Affiliates of any of Eterna Therapeutics Inc., Eterna Therapeutics LLC, and Novellus Therapeutics Limited (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Eterna Entities</u></font>&#8221;), and (b) the Eterna Entities are each deemed not to be Affiliates of any of the Factor Bio Entities.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Agreement</u></font>&#8221; has the meaning set forth in the Preamble.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Applicable Law</u></font>&#8221; means all statutes, ordinances, regulations, rules or orders of any kind whatsoever of any agency, bureau, branch, office, court, commission, authority,
            department, ministry, official or other instrumentality of, or being vested with public authority under any law of, any country, state or local authority or any political subdivision thereof, or any association of countries that may be in
            effect from time to time and applicable to the activities contemplated by this Agreement.</font></font></div>
      <div style="text-align: justify; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Commercially Reasonable Efforts</u></font>&#8221; means, with respect to the performance of activities hereunder by or on behalf of Licensee, the carrying out of such activities using commercial and business
            efforts and resources comparable to the efforts and resources that an entity engaged in out-licensing of technology similar to the inventions disclosed in the Licensed Patents would typically devote to such activities.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidential Information</u></font>&#8221; means all Information disclosed by one Party to the other during the negotiation of or under this Agreement in any manner, whether orally, visually,
            electronically, in writing or in other tangible or intangible form, that relates to Licensed Patents, Licensed Products, or this Agreement, unless such information is subject to an exception described in <font style="font-family: 'Times New Roman';"><u>Section 8.6</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Control</u></font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Controlled by</u></font>&#8221; means, in the context of a license to or ownership of
            Intellectual Property, the ability on the part of a Party to grant access to or a license or sublicense of such Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement between such Party
            and any third party existing at the time such Party would be required hereunder to grant such access or license or sublicense.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Cover</u></font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Covered</u></font>&#8221; means that the use, manufacture, sale, offer for sale, research, development,
            commercialization, importation or other commercial exploitation of the subject matter in question by an unlicensed entity: (a) would infringe an issued Valid Claim (or, in the case of a pending Valid Claim that has not yet issued, would
            infringe such Valid Claim if it were to issue in its then-current form) of a Licensed Patent, or (b) incorporates, uses, or otherwise relies upon the Licensed Patents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-size: 10pt;"><a name="z_Ref126325455"></a><a name="z_Toc94672787"></a><a name="z_Toc94672873"></a><font style="font-family: 'Times New Roman';">1.8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Existing License Agreements</u></font>&#8221; means each agreement set forth on <font style="font-family: 'Times New Roman';"><u>Schedule 1.8</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-size: 10pt;"><a name="z_Ref126325352"></a><font style="font-family: 'Times New Roman';">1.9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Existing Opportunities</u></font>&#8221; means the Opportunities set forth on <font style="font-family: 'Times New Roman';"><u>Schedule 1.9</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Expiration Date</u></font>&#8221; means November 22, 2027.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Exploit</u></font>&#8221; and &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Exploitation</u></font>&#8221; mean to develop, make, have made, manufacture, research, use, sell, have
            sold, offer for sale, commercialize, distribute, import and/or export.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Field</u></font>&#8221; means all human uses.&#160; For the avoidance of doubt, the Field does not include veterinary or agriculture fields.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-size: 10pt;"><a name="z_Toc190788759"></a><font style="font-family: 'Times New Roman';">1.13.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Identify</u></font>&#8221; means with respect to an Opportunity and a third party, the execution of a term sheet between Licensee and such third party for such Opportunity.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.14.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Improvement(s)</u></font>&#8221; means any invention, discovery, advancement, development, or creation which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of
            Licensee, its Sublicensee or an Affiliate of Licensee or its Sublicensee (or any of their respective personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an
            obligation to assign inventions to) them); (b) is not an Independent Invention; and (c) meets at least one of the following criteria: (i) (y) is an improvement or modification to the inventions disclosed in the Licensed Patents, or (z) solely
            with respect to Licensee or its Affiliates (but for clarity, not with respect to any Sublicensees), utilizes, incorporates, or reads upon any element of the inventions disclosed in the Licensed Patents or is invented, developed, authored,
            created, or reduced to practice using the inventions disclosed in the Licensed Patents; or (ii) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensor or an Affiliate of Licensor (or Licensor&#8217;s or its
            Affiliate&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) Licensor or its Affiliates).</font></font></div>
      <div style="text-align: justify; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.15.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Improvement Patents</u></font>&#8221; means the Patents claiming any of the Improvements, and any reissue, divisional, continuation, continuation-in-part or reexamination certificate thereof. During the
            Term, all Improvement Patents shall be set forth in <font style="font-family: 'Times New Roman';"><u>Schedule 1.19</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.16.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Independent Invention</u></font>&#8221; means any invention, discovery, advancement, development, or creation, which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of
            Licensee or an Affiliate of Licensee (or any of the personnel or agents of Licensee or an Affiliate of Licensee, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to
            assign inventions to) Licensee or an Affiliate of Licensee); (b) does not utilize, incorporate, or read upon any element of the inventions disclosed in the Licensed Patents and is not Covered by a Valid Claim; and (c) is not invented,
            developed, authored, created, or reduced to practice by Licensor (or Licensor&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign
            inventions to) Licensor.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.17.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Information</u></font>&#8221; means all information, know-how, data, results, technology, materials, business or financial information of any type whatsoever, in any tangible or intangible form,
            provided by or on behalf of one Party to the other Party, either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement, or that otherwise relates to the Licensed Patents,
            whether disclosed orally, visually, electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices, processes, ideas, research plans, antibodies, small molecules, compounds, targets,
            biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and
            financial and personnel matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or businesses.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.18.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Intellectual Property</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>means <a name="z_Hlk123137569"></a>all (a) Patents; (b) trademarks, service marks,
            trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration thereof; (c) copyrights and registrations and applications for registration thereof, including all moral rights; (d)
            Information, inventions, trade secrets and confidential information, whether patentable or non-patentable and whether or not reduced to practice, know-how, show how, manufacturing and product processes and techniques, research and development
            information, notebooks, formulae, diagrams, technical and engineering specifications, business and marketing plans and customer and supplier lists and other information; (e) other proprietary rights relating to any of the foregoing (including
            remedies against infringement thereof and rights of protection of interest therein under the laws of all jurisdictions); and (f) copies and tangible embodiments thereof.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-size: 10pt;"><a name="z_Ref126325376"></a><font style="font-family: 'Times New Roman';">1.19.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensed Patent</u></font>&#8221; means any Patent Controlled by Licensor or its Affiliates on the Effective Date and during the Term of this Agreement, including the patents and patent applications set forth
          on <font style="font-family: 'Times New Roman';"><u>Schedule 1.19.</u></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.20.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensed </u></font><a name="z_Hlk20583924"></a><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Product</u>&#8221;</font> means any product Covered by the Licensed Patents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.21.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity</u></font>&#8221; means with respect to any third party, the opportunity to grant a sublicense of rights granted to Licensee under this Agreement with respect to, or under the
            applicable Licensed Patent(s) to such third party.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.22.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent</u></font>&#8221; means any patent and provisional and non-provisional patent application, together with all priority application, addition, division, continuation, continuations-in-part,
            substitution, and reissue claiming priority thereto, as well as any reexamination, post-grant proceeding, utility model, certificate of invention and design patents, applications, registrations and applications, extension, registration, patent
            term extension, supplemental protection certificate, renewal and the like with respect to any of the foregoing and all foreign counterparts thereof.</font></font></div>
      <div style="text-align: justify; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.23.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Expenses</u></font>&#8221; means all reasonable fees, costs, and expenses (including attorneys&#8217; fees) paid or incurred in the preparation, filing, prosecution, issuance, and maintenance of the
            Licensed Patents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-size: 10pt;"><a name="z_Ref2677128"></a><font style="font-family: 'Times New Roman';">1.24.</font>&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Pursue</u></font>&#8221; means with respect to an Opportunity and a third party, the process up until and including signing of a definitive agreement between Licensee and such third party for the Opportunity.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.25.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicense Fees</u></font>&#8221; means consideration made to Licensee or any of its Affiliates as consideration for a sublicense of, or other right, license, option, privilege, or immunity with
            respect to, any Licensed Product or any of the rights to the Licensed Patents granted to Licensee hereunder, including without limitation license fees, upfront payments, milestone payments, and royalties payable on sales of Licensed Products.
            For the avoidance of doubt, Sublicense Fees shall include payments made by any Sublicensee to Licensee that are required by an agreement between Licensee and a Sublicensee, wherein said agreement includes the granting of any rights under any of
            the Licensed Patents or the sublicensing of any rights under any of the Licensed Patents, including, without limitation, up-front payments, milestone payments, and royalty payments payable on sales of Licensed Products. To the extent Licensee
            or its Affiliates receives any non-cash consideration, including equity, under or in connection with a sublicense which would be considered &#8220;Sublicense Fee&#8221;, then the fair market value of such non-cash consideration shall be as reasonably
            determined by the Parties and shall be treated as &#8220;Sublicense Fees&#8221; (or if such fair market value cannot be reasonably determined by the Parties, Licensor shall be entitled to such applicable percentage of such non-cash consideration in
            accordance with <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font>).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.26.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicensee</u></font>&#8221; means any third party to which Licensee has granted a sublicense pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.2</u></font>, whether directly
            or indirectly. Notwithstanding the foregoing, none of the Affiliates of Licensee shall be deemed to be a &#8220;Sublicensee&#8221; for purposes of this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.27.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Success Milestone</u></font>&#8221; means actual receipt by Licensee of at least one hundred million U.S. dollars ($100,000,000) in Sublicense Fees from its Sublicensees, including but not limited to upfront
            fees, milestone payments, royalties and other amounts.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.28.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Territory</u></font>&#8221; means worldwide.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.29.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Valid Claim</u></font>&#8221; means: (a) any currently pending claim of a patent application within the Licensed Patents<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, which
              has not been abandoned; </font>or (b) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">a claim of a</font> granted and unexpired and unlapsed patent within the Licensed Patents that (i) has not been revoked, held
            invalid, or declared unpatentable or unenforceable by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal; (ii) has not been rendered or admitted to be
            invalid, abandoned or unenforceable through reissue or disclaimer or otherwise; or (iii) has not been lost through an interference proceeding. However, if a claim of a pending patent application shall not have issued within seven (7) years
            after the filing date of such pending patent application, such claim shall not constitute a Valid Claim for purposes of this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 2</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Licenses</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126243835"></a><font style="font-family: 'Times New Roman';">2.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>License Grant</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to the terms and conditions of this Agreement (including <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font>
        and <font style="font-family: 'Times New Roman';"><u>Section 6.2.1</u></font>), Licensor hereby grants to Licensee an exclusive (even as to Licensor), non-transferrable (except in accordance with <font style="font-family: 'Times New Roman';"><u>Section 11.2</u></font>), royalty-bearing license, with the right to grant sublicenses pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.2</u></font>, under the Licensed Patents to Exploit
        Licensed Products in the Territory in the Field during the Term.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref8627790"></a><font style="font-family: 'Times New Roman';">2.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicensing</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee has the right to sublicense the rights granted to it under <font style="font-family: 'Times New Roman';"><u>Section
            2.1</u></font>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">i.e</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">., without Licensor&#8217;s prior written consent) to any third party pursuant to a written agreement, subject to the following (each, a &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Sublicense Agreement</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;): (a) no Sublicensee of Licensee will have any right to grant further sublicenses to any Affiliate or
          third party; </font>(b) the sublicense is royalty-bearing and in writing, and includes other <a name="z_Hlk127475950"></a>industry standard provisions, including reasonable diligence requirements, patent marking requirements, development and
        commercialization reporting requirements, and insurance requirements, in each case if and to the extent such provisions would customarily be included in such a sublicense based on then-current industry standards; (c) the terms of the Sublicense
        Agreement are consistent with applicable terms and conditions of this Agreement, including, without limitation, <font style="font-family: 'Times New Roman';"><u>Section 7.6</u></font>, as well as the Existing License Agreements; (d) the
        sublicense was negotiated by Licensee in good faith, for a proper commercial purpose and on reasonable arm&#8217;s-length commercial terms; (e) the Sublicense Agreement names Licensor as a third-party beneficiary thereof; (f) the Sublicensee has, or has
        the ability to acquire, adequate resources (including scientific, technical and financial) to perform its obligations under such sublicense, as reasonably determined by Licensee at the time of entry into the sublicense; and (g) a complete,
        confidential copy of the Sublicense Agreement and any amendments thereto are provided to Licensor within thirty (30) days of the execution of said Sublicense Agreement or any such amendments thereto, <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that Licensee may not grant any such sublicense to any thirty party (i) (A) in case of a public company, that is valued at fifty million dollars ($50,000,000) or less (e.g., by
        market capitalization or shareholder equity reflected on such company&#8217;s balance sheet) or (B) in case of a private company, with twenty million dollars ($20,000,000) in cash, in each case, as of the time of entering into the Sublicense Agreement,
        (ii) that is a non-practicing entity (<font style="font-family: 'Times New Roman'; font-style: italic;">e.g</font>., patent troll) that does not conduct any Exploitation activities, as determined by Licensor in its sole discretion or
        (iii) in which Licensee or its Affiliates collectively own or control more than five percent (5%) of such entity, in each case (i) through (iii), without the prior written consent of Licensor, which shall not be unreasonably withheld. In each case,
        Licensee will be responsible for requiring compliance by the applicable counterparty(ies) (i.e., Sublicensees) of such sublicenses entered into by Licensee, and for reasonably enforcing the terms of the sublicenses granted&#160; pursuant to this
        Agreement, including, without limitation, requiring such applicable Sublicensee(s) to make any of the payments provided for hereunder. Subject to <font style="font-family: 'Times New Roman';"><u>Section 8.6</u></font>, Licensee will
        provide Licensor with a complete, confidential copy of each such Sublicense Agreement executed by Licensee and any amendments thereto, and will promptly notify Licensor of the termination of any such sublicense.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126325420"></a><font style="font-family: 'Times New Roman';">2.3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Retained Rights; Requirements</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.3.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Retained Rights</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any and all licenses granted hereunder are subject to (a) Licensor&#8217;s and its Affiliates&#8217; right to use and otherwise perform activities
        under, and to permit academic, government, and not-for-profit institutions or agencies to use and otherwise perform activities under the Licensed Patents (i) both in the Field and outside of the Field and for non-commercial research, academic,
        educational, and all other non-commercial purposes, and (ii) outside of the Field for all commercial and non-commercial purposes, (b) Licensor&#8217;s and its Affiliates&#8217; right to use and otherwise perform activities under the Licensed Patents for the
        provision of commercial contract research services to any person both in the Field and outside the Field, and (c) any licenses or other rights granted by Licensor to third parties under the Existing License Agreements. Subject to the terms of this
        Agreement, any commercial provision of a contract research services agreement entered into by Licensor or its Affiliates with a third party that requires Licensor to grant such third party a license under the Licensed Patents in the Field will be
        subject to a written agreement between Licensor and such third party that grants such third party a license under the Licensed Patents to conduct (or use, as applicable) such services (including deliverables provided thereunder) only for
        non-commercial purposes in the Field.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 4.5pt; margin-left: 103.5pt; font-size: 10pt;"><a name="z_Ref126681109"></a><font style="font-family: 'Times New Roman';">2.3.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Right to Publish</u></font>.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to this <font style="font-family: 'Times New Roman';"><u>Section 2.3.2</u></font>, any and all licenses granted
        hereunder are subject to the right of Licensor to review publication of scientific findings related to the Licensed Patents. If Licensee desires to submit any publication related to the Licensed Patents or that would otherwise disclose Confidential
        Information of Licensor or any patentable information related to Licensed Patents, Licensee will provide Licensor with prior written notice of such proposed publication and a copy of such proposed publication. Licensor will use reasonable efforts
        to complete its review of such proposed publication promptly, and in any event will complete its review within thirty (30) days of receipt of the proposed publication (or ten (10) days in case of abstracts), provided that Licensor shall be deemed
        to have given its consent if Licensor does not complete its review within such thirty (30) or ten (10) days, as applicable. Licensor shall notify Licensee of any Licensor Confidential Information contained in such proposed publication and, in
        response to such notification, Licensee will promptly delete any Licensor Confidential Information from the proposed publication that a Licensor has identified during such thirty (30) day review period. Licensor will have the right to delay
        submission of the proposed publication for up to an additional thirty (30) days if such Licensor determines, in its sole discretion, that publication of the proposed publication would have negative effects on Licensor&#8217;s patent rights. In the event
        that Licensor decides to delay submission of the proposed publication, Licensor shall inform Licensee of such decision within the initial thirty (30) day review period, and the Parties shall reasonably cooperate in order to resolve any concerns
        with the proposed publication within such review period (as may be extended if the publication has already been submitted).</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 4.5pt; margin-left: 103.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.3.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>U.S. Federal Funding</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any and all licenses granted under patents supported by U.S. federal funding are subject to the rights, conditions, and limitations
        imposed by U.S. law (see 35 U.S.C. &#167;202 <font style="font-family: 'Times New Roman';"><u>et seq</u></font>. and regulations pertaining thereto), including without limitation: (i) the royalty-free, non-exclusive license granted to the
        U.S. government; and (ii) the requirement that any products covered by an issued claim and sold in the U.S. will be substantially manufactured in the United States. Licensee agrees to inform Licensor of those Improvements that are developed,
        reduced to practice or invented by Licensee&#8217;s personnel and agents or the personnel or agents of Licensee&#8217;s Affiliates or Sublicensees (or that are Controlled by Licensee or Licensee&#8217;s personnel or agents or the personnel or agents of Licensee&#8217;s
        Affiliates or Sublicensees) during the Term and beyond with the support (either entirely or in part) of U.S. federal funding, and to provide all information and documentation to Licensor that Licensor may request to secure patent rights for those
        inventions, including, but not limited to, grant numbers, contract numbers, and names of granting and contracting institutions and organizations.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 3</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Reservation of Rights</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 40.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>No Grant of Other Technology or Patent Rights</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party understands and acknowledges that the other Party owns its own Intellectual Property and all rights therein. Except as
        otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or license, or be deemed to obtain any ownership interest or license, in or to any technology,
        know-how, patents, patent applications, products, or materials of the other Party, including, but not limited to, items Controlled or developed by the other Party, at any time pursuant to this Agreement. This Agreement does not create, and shall
        under no circumstances be construed or interpreted as creating, an obligation on the part of either Party to grant any license to the other Party other than as expressly set forth herein. Any further contract or license agreement between Licensor
        and Licensee shall be in writing. No licenses are implied by Licensor to Licensee, except as specifically stated in this Agreement. Except as explicitly set forth in this Agreement, Licensor shall not be deemed by estoppel or implication to have
        granted Licensee any license or other right to any Intellectual Property of Licensor or its Affiliates.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Reserved Rights</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">All rights and interests not expressly granted to Licensee under this Agreement are reserved by Licensor (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Reserved Interests</u></font>&#8221;) for itself, its licensors, and other licensees and sublicensees. <a name="z_DV_M68"></a>It shall not be a breach of this Agreement for Licensor, acting directly
        or indirectly, to exploit its Reserved Interests in any manner anywhere in the Territory.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc473140459"></a>Section 4</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Diligence</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">
        <div style="font-family: 'Times New Roman'; margin-left: 36pt;"><a name="z_Ref2682778" id="z_Ref2682778"></a><font style="font-family: 'Times New Roman';">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee Responsibilities</u></font>.</div>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.1.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee will use
            Commercially Reasonable Efforts to Identify and Pursue Opportunities.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.1.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee shall
            provide Licensor semi-annual written updates on Licensee&#8217;s activities hereunder, and on each Sublicensee&#8217;s Licensed Product development and commercialization activities in the Field in the Territory, beginning as of the date of the applicable
            Sublicense Agreement, which updates shall be provided to Licensor at least every six (6) months during the Term and upon Licensor&#8217;s reasonable request therefor, and Licensor shall have the right to reasonably request additional information
            regarding Licensee&#8217;s (or each Sublicensee&#8217;s) progress in this regard. Such updates will include the activities undertaken by or on behalf of Licensee since the last report was delivered; and the activities to be undertaken by or on behalf of
            Licensee (or each applicable Sublicensee) during the next twelve (12)-month period and the expected timing of such activities (including the estimated dates of initiation and completion of such activities).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref126326349"></a>Section 5</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Consideration; Records &amp; Reports</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref126252756"></a><font style="font-family: 'Times New Roman';">5.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Royalties on Sublicense Fees</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee shall, within thirty (30) days of receipt of any Sublicense Fees, (a) pay to Licensor (i) twenty percent (20%) of any such
        Sublicense Fees received in connection with any Existing Opportunities, or Opportunities Identified during the Initial Term and (ii) thirty percent (30%) of any such Sublicense Fees received in connection with any Opportunities Identified during
        the Renewal Term, and (b) provide to Licensor a report specifying the source and nature of the Sublicense Fees, the gross amount of Sublicense Fees received, any applicable fees, credits or deductions permitted pursuant to this Agreement, and the
        net amount of Sublicense Fees payable to Licensor. Licensee shall pay in U.S. dollars all amounts due to Licensor pursuant to this Agreement. All payments due to Licensor hereunder shall be made by wire transfer of immediately available funds into
        an account designated by Licensor.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Audit and Inspection Rights</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee and its Affiliates and Sublicensees will maintain complete and accurate records in sufficient detail to permit Licensor to
        confirm the accuracy of the calculation of payments under this Agreement. Upon reasonable prior notice, such records shall be available during regular business hours (without undue disruption of Licensee&#8217;s business) for a period of three (3) years
        from the end of the calendar year to which they pertain for examination by an independent accountant selected by the Licensor and reasonably acceptable to Licensee, for the sole purpose of verifying the accuracy of the reports and payments
        furnished by Licensee pursuant to this Agreement. Audits may not be requested more than once per year, and no period may be audited more than once. Any such auditor shall enter into a confidentiality agreement with Licensee, and shall not disclose
        Licensee&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the amount of payments due by Licensee to Licensor under this Agreement. The auditor may not be
        compensated on a commission, bonus, or any other payment that depends on the result of the audit or amounts due or paid as a result of the audit. Any undisputed amounts shown to be owed but unpaid shall be paid within thirty (30) days from the
        accountant&#8217;s report, plus interest (as set forth in <font style="font-family: 'Times New Roman';"><u>Section 5.4</u></font>) from the original due date. Licensor shall bear the full cost of such audit.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Taxes</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the
        efforts of the Parties under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of payments made by a Party to the other Party under
        this Agreement. To the extent Licensee is required to deduct and withhold taxes on any payment to Licensor hereunder, Licensee shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to
        Licensor an official tax certificate or other evidence of such withholding sufficient to enable Licensor to claim such payment of taxes. Licensor shall provide the Licensee with any tax forms that may be reasonably necessary in order for the
        Licensee to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding
        taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326000"></a><font style="font-family: 'Times New Roman';">5.4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late Payment</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If Licensor does not receive payment of any sum due to it on or before the due date (each, a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late Payment</u></font>&#8221;), Licensee shall pay to the applicable Licensor an amount equal to five percent (5%) of such Late Payment (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late
            Payment Penalty</u></font>&#8221;), and such Late Payment shall not be considered paid in full until Licensor has received from Licensee both the full amount of such Late Payment and the Late Payment Penalty. For the avoidance of doubt, payment by
        Licensee within thirty (30) days past the due date will not be considered a Late Payment subject to a Late Payment Penalty.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 6</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Warranties</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">
        <div style="font-family: 'Times New Roman'; margin-left: 36pt;"><a name="z_Ref126326187" id="z_Ref126326187"></a><a name="z_Hlk126244102" id="z_Hlk126244102"></a><font style="font-family: 'Times New Roman';">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representations, Warranties and Covenants of Licensor</u></font>.</div>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that, as of the Effective Date, the Patents identified on <font style="font-family: 'Times New Roman';"><u>Schedule 1.19</u></font> are all the patents owned or licensed by Licensor in the
            Territory. Licensor hereby represents and warrants to Licensee that, as of the Effective Date, it is the sole and exclusive owner or licensee of the Licensed Patents, and it has the right, power and authority to grant the rights set forth in <font style="font-family: 'Times New Roman';"><u>Section 2.1</u></font> of this Agreement. Licensor hereby covenants to Licensee that it will, during the Term, at Licensee&#8217;s reasonable request from time to time, update <font style="font-family: 'Times New Roman';"><u>Schedule 1.19</u></font>.</font></font></div>
      <div style="text-align: justify; text-indent: 81pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.2</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that, as of the Effective Date and for the entire Term of this Agreement, the execution and performance of Licensor&#8217;s obligations under this Agreement do not conflict with, cause a default under, result in a
            breach of or violate any existing contractual obligation that may be owed by Licensor to any third party, including, without limitation, any Affiliate of Licensor, nor will Licensor, during the Term of this Agreement, take any action, inaction
            or enter into agreement that would conflict with, cause a default under, result in a breach of or violate any existing contractual obligation that is owed to Licensee under this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that it has full power and authority to execute, deliver and perform this Agreement and that this Agreement constitutes the legally binding and valid obligation of Licensor, enforceable in accordance with its
            terms, except as such enforcement may be limited by applicable bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that (i) there are no liens or other encumbrances on the Licensed Patents or any part thereof which would interfere with the rights granted to Licensee under this Agreement (which for clarity, are subject to
            the Existing License Agreements) and (ii) Licensor will not take any actions after the Effective Date of this Agreement that would be inconsistent with the rights granted Licensee under this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that there is no action or suit pending against Licensor that questions the validity of this Agreement or the right of Licensor to enter into this Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>or consummate the transactions contemplated hereby.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref126683294"></a><font style="font-family: 'Times New Roman';">6.1.6</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
          covenants to Licensee that during the Term, it will not grant any licenses under the Licensed Patents to any third party in the Field, without the prior consent of Licensee, provided that for clarity, Licensor shall have the right to grant any
          licenses to (i) any third party acting solely as a distributor, contract manufacturer or contract research organization, (ii) its Affiliates, (iii) as set forth in <font style="font-family: 'Times New Roman';"><u>Section 2.3.1</u></font>
          of this Agreement, or (iv) as set forth in the Existing License Agreements.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 76.5pt; font-size: 10pt;"><a name="z_Ref126248868"></a><font style="font-family: 'Times New Roman';">6.1.7</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
          represents and warrants to Licensee that, except as previously disclosed to Licensee there is no action or suit pending against Licensor that would adversely and materially impact Licensor&#8217;s business or operations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.8</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            represents and warrants to Licensee that, except as previously disclosed to Licensee, there is no action or suit pending against Licensor affecting the validity of the Licensed Patents or the ownership of Licensed Patents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.9</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            covenants to Licensee that it will, during the Term, inform Licensee of any Opportunities it becomes aware of, provided that doing so does not violate any obligation of confidentiality owed by Licensor to such third party, or will refer such
            Opportunities to Licensee.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.10</font><font style="font-size: 10pt;">&#160; <font style="font-family: 'Times New Roman';">Licensor hereby
            covenants to Licensee that it will not, during the Term, amend or modify any of the Existing License Agreements in a manner that would adversely affect or otherwise be in conflict with the rights granted to Licensee hereunder, without
            Licensee&#8217;s consent.</font></font></div>
      <div style="text-align: justify; text-indent: 76.5pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representations, Warranties and Covenants of Licensee</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref126325506"></a><font style="font-family: 'Times New Roman';">6.2.1</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
          represents and warrants to Licensor that, as of the Effective Date, and for the entire Term of this Agreement, the execution and performance of Licensee&#8217;s obligations under this Agreement do not conflict with, cause a default under, or result in
          a breach of or violate any existing contractual obligation that may be owed by Licensee to any third party, including, without limitation, any Affiliate of Licensee, nor will Licensee, during the Term of this Agreement, take any action, inaction
          or enter into agreement that would conflict with, cause a default under, result in a breach of or violate (i) any existing contractual obligation that is owed to Licensor under this Agreement or (ii) the terms of the Existing License Agreements.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
            represents and warrants to Licensor that it has full power and authority to execute, deliver and perform this Agreement and that this Agreement constitutes the legally binding and valid obligation of Licensee, enforceable in accordance with its
            terms, except as such enforcement may be limited by applicable bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
            represents and warrants to Licensor that there is no action or suit pending against Licensee or any of its Affiliates that questions the validity of this Agreement or the right of Licensee to enter into this Agreement or consummate the
            transactions contemplated hereby, and neither Licensee nor any of its Affiliates is a party to any litigation, arbitration, mediation or other similar legal proceeding.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
            covenants to Licensor that during the Term, it will not Exploit any Licensed Product by itself or through any Affiliate of Licensee (and for clarity, or through any successors or permitted assigns) absent a separate written agreement between
            Licensor and Licensee containing industry standard provisions, including economic terms, diligence requirements, patent marking requirements, development and commercialization reporting requirements, and insurance requirements, in each case if
            and to the extent such provisions would customarily be included in such an agreement based on then-current industry standards.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref126677057"></a><font style="font-family: 'Times New Roman';">6.2.5</font>&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
          covenants to Licensor that during the Term, it will not Pursue any Opportunity for which it does not have resources sufficient to Pursue, including, without limitation, financial resources necessary to defend any claim, action or proceeding that
          may arise as a result of or in connection with such Pursuit.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref126677062"></a><font style="font-family: 'Times New Roman';">6.2.6</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby
          covenants to Licensor that during the Term, in the event of any dispute or disagreement between Licensor and Licensee as to the Pursuit of any Opportunity that could reasonably result in irreparable harm to the validity or enforceability of one
          or more Licensed Patents, Licensee shall immediately cease Pursuing any Opportunities that are the subject of such dispute or disagreement, and shall not resume Pursuing any such Opportunities unless and until such dispute or disagreement is
          resolved in accordance with <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Disclaimer</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except as expressly provided in <font style="font-family: 'Times New Roman';"><u>Section 6.1</u></font>, nothing in this
        Agreement will be construed as:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">a warranty or
            representation by Licensor as to the validity or scope of any of the Licensed Patents;</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.2</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">a warranty or
            representation by Licensor that anything made, used, sold or otherwise disposed of under the licenses granted in this Agreement, or the practice of the Licensed Patents, will or will not infringe patents of third parties; or</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">an obligation of
            Licensor to bring or prosecute actions or suits against third parties for infringement of Licensed Patents.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Express Disclaimer</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, LICENSOR IS PROVIDING THE LICENSED PATENTS &#8220;AS IS.&#8221; EXCEPT AS EXPRESSLY PROVIDED IN THIS
        AGREEMENT,<font style="font-family: 'Times New Roman'; font-style: italic;">&#160;</font>NEITHER LICENSOR NOR LICENSEE MAKES ANY REPRESENTATIONS, EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY
        IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR AS TO THE VALIDITY OF ANY PATENTS, AND LICENSOR DOES NOT ASSUME ANY RESPONSIBILITY WHATSOEVER WITH RESPECT TO USE, SALE, OR
        OTHER DISPOSITION OF PRODUCTS INCORPORATING OR MADE BY USE OF LICENSED PATENTS IN CONNECTION WITH THIS AGREEMENT.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="font-family: 'Times New Roman'; margin-left: 36pt;">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Exclusion of Consequential and Other Direct Damages</u></font>.</div>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 31.7pt; font-family: 'Times New Roman'; font-size: 10pt;">TO THE FULLEST EXTENT PERMITTED BY LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR ANY INJURY TO OR LOSS OF
        GOODWILL, REPUTATION, BUSINESS PRODUCTION, REVENUES, PROFITS, ANTICIPATED PROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR
        ENHANCED DAMAGES, WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH LOSS OR
        DAMAGE WAS FORESEEABLE AND THE PARTY AGAINST WHOM LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED REMEDY OF ITS ESSENTIAL PURPOSE. THE FOREGOING LIMITATIONS WILL NOT:
        (A) APPLY TO INFRINGEMENT BY A PARTY OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY RIGHTS OR A PARTY&#8217;S BREACH OF <font style="font-family: 'Times New Roman';"><u>SECTIONS 8.6</u></font> OR <font style="font-family: 'Times New Roman';"><u>11.13</u></font>, OR (B) LIMIT A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER <font style="font-family: 'Times New Roman';"><u>Section 9</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_DV_M93"></a><a name="z_Ref126326289"></a>Section 7</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Term and Termination</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The term of this Agreement will begin on the Effective Date and will expire, in its entirety, on the Expiration Date (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Initial Term</u></font>&#8221;) unless earlier terminated under the provisions of this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>; provided
        however that, the Initial Term shall automatically extend for an additional two and a half (2.5) years (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Renewal Term</u></font>&#8221;, together with the Initial Term,
        the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term</u></font>&#8221;) if the Success Milestone has been met during the Initial Term.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref45024744"></a><font style="font-family: 'Times New Roman';">7.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination by Licensor</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensor may, at its option, terminate this Agreement, upon written notice to Licensee of any of the following events or otherwise as
        provided in this Agreement:</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, any material breach of any of Licensee&#8217;s obligations under this Agreement, which Licensee fails to remedy within ninety (90) days after
            receipt of written notice by Licensor of such material breach and Licensor&#8217;s demand that it be cured, and for avoidance of doubt, once the provisions of <font style="font-family: 'Times New Roman';"><u>Section 10</u></font> are
            triggered, the ninety (90) day cure period is tolled pending the Alternative Dispute Resolution procedures and timing set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, the filing in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy
            or insolvency or for reorganization or for an arrangement or for the <a name="z_Ref26881013"></a>appointment of a receiver or trustee or if Licensee is served with an involuntary petition against it, filed in any insolvency proceeding, and
            such petition is not dismissed within sixty (60) days after the filing thereof, or if Licensee will propose or be a party to any dissolution or liquidation, or if Licensee will make an assignment for the benefit of its creditors, or if at any
            time Licensee voluntarily enters into proceedings for winding up or dissolution of business; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, if Licensee provides for the cure of all
            of its defaults under this Agreement (if any) and provides adequate assurance of its future performance of its obligations, then Licensor shall not have the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7.2.2</u></font>;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 5</u></font>, Licensee&#8217;s failure to timely make any payment required to be made to Licensor as set forth in <font style="font-family: 'Times New Roman';"><u>Section 5</u></font> or <font style="font-family: 'Times New Roman';"><u>Section 8.2</u></font>, which Licensee fails to remedy within thirty (30) days after receipt of written notice by Licensor of such failure
            and Licensor&#8217;s demand that it be cured;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">any breach of
            Licensee&#8217;s obligations under <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font>, which Licensee fails to remedy within sixty (60) days after receipt of written notice by Licensor and Licensor&#8217;s demand that it
            be cured;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.5</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Licensee&#8217;s failure
            to comply with the obligation to <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">maintain in full force and effect the required insurance coverage in accordance with <u>Section </u></font><font style="font-family: 'Times New Roman';"><u>9.3</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>, </u></font>which
            Licensee fails to remedy within ninety (90) days after receipt of written notice by Licensor of such material breach and Licensor&#8217;s demand that it be cured; or</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">any material
            breach by a Sublicensee of the applicable Sublicense Agreement entered into between Licensee and such Sublicensee, which (i) Sublicensee fails to remedy within ninety (90) days after receipt of written notice by Licensor of such material breach
            and Licensor&#8217;s demand that it be cured, and (ii) which sublicense Licensee fails to so terminate within thirty (30) days after Licensor&#8217;s demand given after such failure to remedy.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.7</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In addition,
            Licensor may, at its option, terminate this Agreement on a Licensed Patent-by-Licensed Patent basis upon written notice to Licensee, in the event that (i) such Licensed Patent has not been sublicensed by Licensee under this Agreement and (ii)
            Licensee has not Identified an Opportunity for such Licensed Patent, in each case, within the later of (a) three (3) years from the Effective Date or (b) three (3) years of the date of grant of such Licensed Patent (i.e., such Licensed Patent
            has been granted issuance and is no longer a pending application).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.8</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, nothing in the foregoing subsections of this <font style="font-family: 'Times New Roman';"><u>Section 7.2</u></font> shall
            prohibit Licensor from pursuing any and all rights and remedies it may have under this Agreement or at law or in equity. For the avoidance of doubt, Licensor&#8217;s right to terminate under <font style="font-family: 'Times New Roman';"><u>Sections
                7.2.3</u></font>, or <font style="font-family: 'Times New Roman';"><u>7.2.4</u></font> shall not be subject to the provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, shall
            not expire, and any such termination shall take effect upon written notice to Licensee.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326750"></a><font style="font-family: 'Times New Roman';">7.3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination by Licensee</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee may, at its option, terminate this Agreement in its entirety, upon written notice to the Licensor of any of the following events
        or otherwise as provided in this Agreement:</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.1</font><font style="font-size: 10pt;">&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">at any time, by
            giving at least one hundred and twenty (120) days prior written notice of such termination to Licensor;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, upon any material breach of Licensor&#8217;s express representations, warranties or covenants set forth in <font style="font-family: 'Times New Roman';"><u>Section 6.1</u></font>, which Licensor fails to remedy within sixty (60) days after receipt of written notice by Licensee of such material breach and Licensee&#8217;s demand that it be cured, and for avoidance of
            doubt, once the provisions of <font style="font-family: 'Times New Roman';"><u>Section 10</u></font> are triggered, the sixty (60) day cure period is tolled pending the Alternative Dispute Resolution procedures and timing set forth
            in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, any material breach of any of Licensor&#8217;s obligations under this Agreement, which Licensor fails to remedy within ninety (90) days after
            receipt of written notice by Licensee of such material breach and Licensee&#8217;s demand that it be cured, and for avoidance of doubt, once the provisions of <font style="font-family: 'Times New Roman';"><u>Section 10</u></font> are
            triggered, the ninety (90) day cure period is tolled pending the Alternative Dispute Resolution procedures and timing set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>; or</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, the filing in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy
            or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee or if Licensor is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed
            within sixty (60) days after the filing thereof, or if Licensor will propose or be a party to any dissolution or liquidation, or if Licensor will make an assignment for the benefit of its creditors, or if at any time Licensor voluntarily enters
            into proceedings for winding up or dissolution of business; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, if Licensor provides for the cure of all of its defaults under this
            Agreement (if any) and provides adequate assurance of its future performance of its obligations, then the Licensee shall not have the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section
                7.3.4</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the
            provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>, nothing in the foregoing subsections of this <font style="font-family: 'Times New Roman';"><u>Section 7.3</u></font> shall
            prohibit Licensee from pursuing any and all rights and remedies it may have under this Agreement or at law or in equity.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Challenging Validity</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except to the extent unenforceable under Applicable Law in the Territory, Licensor may terminate this Agreement by written notice to
        Licensee in the event of a breach of <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font> by Licensee, its Affiliates or Sublicensees or in the event that Licensee or any of its Affiliates challenges, in any formal
        proceeding, the validity, patentability, enforceability, scope, construction or inventorship of any of the Licensed Patents or assists any third party in any such challenge (each, a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Challenge</u></font>&#8221;). If a Sublicensee of Licensee brings any such Patent Challenge or assists a third party in bringing any such Patent Challenge (except as required under a court order or subpoena), then
        Licensor may send a written demand to Licensee to terminate such sublicense. If Licensee fails to so terminate such sublicense within thirty (30) days after Licensor&#8217;s demand, Licensor may terminate this Agreement. In any country(ies) where
        Licensor may not terminate this Agreement in the event of a Patent Challenge, if: (i) Licensee brings a Patent Challenge against Licensor; (ii) Licensee assists a third party in bringing a Patent Challenge against Licensor (except as required under
        a court order or subpoena); or (iii) a Sublicensee of Licensee brings a Patent Challenge or assists a third party in bringing a Patent Challenge (except as required under a court order or subpoena), Licensor sends a written demand to Licensee to
        terminate such sublicense, and Licensee fails to so terminate such sublicense within thirty (30) days after Licensor&#8217;s demand, and such Patent Challenge is not successful (<font style="font-family: 'Times New Roman'; font-style: italic;">i.e.,
        </font>the Licensed Patent(s) subject to such Patent Challenge retain Valid Claims), then the applicable percentage of Sublicense Fees payable under <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font> shall be
        doubled. In the event that such a Patent Challenge is successful, Licensee will have no right to recoup any payments made during the period of such Patent Challenge.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126677268"></a><font style="font-family: 'Times New Roman';">7.5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effects of Termination; Termination of License</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.5.1</font><font style="font-size: 10pt;">&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Upon termination or
            expiration of this Agreement for any reason, Licensee&#8217;s rights to the Licensed Patents, inclusive of the Licensed Products, which have been granted hereunder and all use thereof will terminate, any and all rights in the Licensed Patents,
            inclusive of the Licensed Products, will revert back to Licensor. Notwithstanding the foregoing, in event of expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement,
            Licensee and Licensor shall cooperate in Pursuing Opportunities that Licensee has Identified prior to the effective date of expiration of this Agreement for up to one (1) year from the effective date of expiration of this Agreement, and
            Licensee shall collect its applicable share of Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor under any such licenses entered into by Licensor with
            respect to such Identified Opportunities during such one (1) year period, provided that such Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor should be
            treated as Sublicense Fees hereunder and shared between Licensee and Licensor in accordance with <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font> and such license shall survive in accordance with <font style="font-family: 'Times New Roman';"><u>Section 7.6</u></font> below (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>). Licensee&#8217;s right to Pursue the Opportunities pursuant to
            this <font style="font-family: 'Times New Roman';"><u>Section 7.5.1</u></font> is expressly made subject to applicable provisions of this Agreement, including the covenants of Licensee set forth in <font style="font-family: 'Times New Roman';"><u>Sections 2.2</u></font>, and <font style="font-family: 'Times New Roman';"><u>6.2</u></font>, which shall survive any expiration of this Agreement with respect to such Opportunities (and for
            clarity, Licensee&#8217;s foregoing right to Pursue the Opportunities shall terminate for Licensee&#8217;s material breach by of such surviving provisions).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.5.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">During the Term,
            Licensee may, subject to Licensor&#8217;s prior written consent (such consent not to be unreasonably withheld), identify two (2) Opportunities, whether or not such Opportunities are Identified Opportunities, as &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Surviving Opportunities</u></font>&#8221;. Notwithstanding anything to the contrary, Licensee and Licensor shall cooperate in Pursuing the Surviving Opportunities for up to four (4) years from the effective
            date of expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement, and Licensee shall collect its applicable share of Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor under any such licenses entered into with respect to such Surviving Opportunities that are Identified during such four (4) year period, provided
            that such Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor should be treated as Sublicense Fees hereunder and shared between Licensee and Licensor in
            accordance with <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font> and such license shall survive in accordance with <font style="font-family: 'Times New Roman';"><u>Section 7.6</u></font> below (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>). Licensee&#8217;s right to Pursue the Surviving Opportunities is expressly made subject to the applicable provisions of this Agreement, including the
            covenants of Licensee set forth in <font style="font-family: 'Times New Roman';"><u>Sections 2.2</u></font> and <font style="font-family: 'Times New Roman';"><u>6.2</u></font>, which shall survive any expiration of this
            Agreement with respect to such Surviving Opportunities (and for clarity, Licensee&#8217;s foregoing right to Pursue the Surviving Opportunities shall terminate for Licensee&#8217;s material breach of such surviving provisions).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126325570"></a><font style="font-family: 'Times New Roman';">7.6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effect on Sublicenses</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In the event that this </font><font style="font-size: 10pt;">Agreement <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">is terminated or expires</font> for any reason<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, and if </font>Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">requests that any given sublicense(s) survive such termination (each, a &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Surviving Sublicense</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;), such Surviving Sublicense(s) shall be considered a direct </font>license <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">from </font>Licensor <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">to such surviving Sublicensee, unless such Sublicensee is (a) an Affiliate of Licensee, (b) in material
            default of any provision of the applicable sublicense, or (c) the basis for termination of this Agreement is due to such Sublicensee&#8217;s actions or inactions ((a)-(c), an &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Ineligible Sublicensee</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;)</font>; provided that such Sublicensee agrees in writing that (i) Licensor is entitled to enforce
          all relevant provisions directly against such Sublicensee, and (ii) Licensor shall not assume, and shall not be responsible to such Sublicensee for, any representations, warranties or obligations of Licensee to such Sublicensee, other than to
          permit such Sublicensee to exercise any rights to <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the </font>Licensed Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">sublicensed
            to such Sublicensee by </font>Licensee, to the extent consistent with the terms of this Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. For clarity, in the event that this Agreement expires (but for
            clarity, not in the event that this Agreement is terminated for any reason), any Sublicense Fees (</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">mutatis mutandis</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">) received by Licensor pursuant to the Surviving Sublicenses should be treated as Sublicense Fees under this Agreement and shared between Licensee and Licensor in accordance
            with <u>Section 5.1</u>.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326838"></a><font style="font-family: 'Times New Roman';">7.7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Accrued Obligations</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Expiration or termination of this Agreement will not release either Party from any obligation that matured prior to the effective date of
        such expiration or termination. Upon expiration or termination of this Agreement for any reason, any unpaid amounts payable to Licensor shall become immediately due, and payment thereof shall remain an ongoing obligation of Licensee until such
        amount is paid in full.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Survival</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Upon expiration or termination of this Agreement, <font style="font-family: 'Times New Roman';"><u>Sections 1</u></font>, <font style="font-family: 'Times New Roman';"><u>2.3</u></font>, <font style="font-family: 'Times New Roman';"><u>3</u></font>, <font style="font-family: 'Times New Roman';"><u>5.4</u></font>, <font style="font-family: 'Times New Roman';"><u>6.4</u></font>, <font style="font-family: 'Times New Roman';"><u>6.5</u></font>, <font style="font-family: 'Times New Roman';"><u>7.5-7.8</u></font> (provided that, all applicable provisions
        of this Agreement, including <font style="font-family: 'Times New Roman';"><u>Sections 2.2</u></font> and <font style="font-family: 'Times New Roman';"><u>4.1</u></font> shall survive to the extent applicable with respect to <font style="font-family: 'Times New Roman';"><u>Section 7.5</u></font>), <font style="font-family: 'Times New Roman';"><u>8.1</u></font>, <font style="font-family: 'Times New Roman';"><u>8.6</u></font>, and <font style="font-family: 'Times New Roman';"><u>9-11</u></font> will, with related definitions, survive and remain in full force and effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 8</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Intellectual Property Rights</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326485"></a><font style="font-family: 'Times New Roman';">8.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Rights in Improvements, Improvement Patents and Independent Inventions</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the
            rights granted to Licensee in <font style="font-family: 'Times New Roman';"><u>Section 2.1</u></font> and <font style="font-family: 'Times New Roman';"><u>Section 2.2</u></font>, Licensor shall own, and Licensee shall
            assign and hereby does assign (and shall ensure that all of its Sublicensees assigns), to Licensor all right, title and interest in and to all Improvements and Improvement Patents, including all related certificates of correction, reissue
            certificates, and supplementary protection certificates, and all other rights granted under 35 U.S.C. &#167; 307, 35 U.S.C. &#167; 318, 35 U.S.C. &#167; 328, and 35 U.S.C. &#167; 254-257. Licensee shall execute and assist (and ensure that its Sublicensees execute
            and assist) with any and all applications, assignments, or other instruments which Licensor deems necessary to perfect the foregoing assignment and/or to evidence, apply for, obtain, maintain, defend or enforce patent or other intellectual
            property protection in any and all countries worldwide with respect to Improvements assigned to Licensor as set forth above or to protect otherwise Licensor&#8217;s interest therein.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee shall own
            all right, title and interest in and to all Independent Inventions invented, developed, created, or reduced to practice by or on behalf of Licensee.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Improvement Patents
            shall be automatically included as part of the Licensed Patents. Licensee and Licensor agree promptly to update <font style="font-family: 'Times New Roman';"><u>Schedule 1.19</u></font> of this Agreement attached hereto upon written
            request by either Party from time to time, to reflect the inclusion of such Improvement Patents in the Licensed Patents. Each Party will use reasonable efforts to disclose to the other Party during the Term any and all Improvements and
            Improvement Patents and Licensee and Licensor agree promptly to update <font style="font-family: 'Times New Roman';"><u>Schedule 1.19</u></font> upon written request by either Party from time to time, to reflect the inclusion of any
            Improvement Patents.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126327348"></a><font style="font-family: 'Times New Roman';">8.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Prosecution</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the Term, as between the Parties, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor </font>will
        be responsible for preparing, filing, prosecuting and maintaining all patent applications and patents included in the Licensed Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">in the Territory. </font>For the
        sake of clarity, as used herein the term &#8220;prosecution&#8221; shall include interference, opposition, and derivation proceedings, <font style="font-family: 'Times New Roman'; font-style: italic;">ex parte</font> reexaminations, <font style="font-family: 'Times New Roman'; font-style: italic;">inter partes</font> reviews, post-grant reviews, and appeals of each of the foregoing (and any foreign equivalents) in connection with the Licensed Patents. Licensor, with
        Licensee&#8217;s consent not to be unreasonably withheld, shall select patent counsel to conduct such activities regarding the <a name="z_Hlk65238093"></a>Licensed Patents<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>and
        shall keep Licensee informed of prosecution activities for Licensed Patents<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>providing Licensee an opportunity to provide comments. Licensor shall cause all patent
        applications and patents included in the Licensed Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">in the Territory</font> to be diligently prosecuted, and in the event Licensor decides to irrevocably
        discontinue prosecution of any patent applications included in the Licensed Patents, or irrevocably allow any patents included in the Licensed Patents to lapse, subject at all times to the rights granted by Licensor under the Existing License
        Agreements, Licensor shall provide Licensee notice thereof in accordance with <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font>. All Patent Expenses will be borne by Licensee, including such Patent Expenses that
        were incurred prior to the Effective Date. At Licensor&#8217;s request, Licensee shall enter into third-party payer agreements with Licensor&#8217;s patent counsel.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">
        <div style="font-family: 'Times New Roman'; margin-left: 36pt;">8.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee&#8217;s Right to Take Over Prosecution or Pay Fees</u></font>.</div>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject at all times to the rights granted by Licensor under the Existing License Agreements, in the event that <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor</font> decides to irrevocably discontinue prosecution of any patent applications included in the Licensed Patents without filing a continuation or divisional application, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor</font> will notify <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> thereof within such time as may be reasonably
        necessary for <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> to continue such prosecution on the applicable Licensor&#8217;s behalf, and <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> will <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">have the right, but not the obligation, to so continue such prosecution at its own cost and expense. </font>In the event that <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor</font> decides to allow any patents included in the Licensed Patents to lapse as a result of nonpayment of an annuity, maintenance fee, or equivalent, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor</font> will notify <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> thereof within such time as may be reasonably
        necessary for <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> to make such payment on Licensor&#8217;s behalf, and <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font>
        will <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">have the right, but not the obligation, to pay the </font>annuity, maintenance fee, or equivalent<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> at its own cost and expense.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_DV_M173"></a><a name="z_DV_M177"></a><a name="z_DV_M178"></a><a name="z_DV_M180"></a><font style="font-family: 'Times New Roman';">8.4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Enforcement of Licensed Patents</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Notice</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If either Party becomes aware of any infringement in the Field, anywhere in the Territory, of any issued patent within the Licensed
        Patents, such Party will notify the other Party in writing within thirty (30) days to that effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326955"></a><font style="font-family: 'Times New Roman';">8.4.2.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Infringement of Licensed Patents by Third Parties</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject at all
            times to the rights granted by Licensor under the Existing License Agreements, in the case of any infringement of any Licensed Patent in the Field by any third party, the Licensee will have the first right, but not the obligation, to cause such
            third party to cease infringement and to otherwise enforce such Licensed Patent or to defend the Licensed Patent in any declaratory judgment action brought by third party(ies) which alleges the invalidity, unenforceability or non-infringement
            of the rights associated with the Licensed Patent. Before commencing any such enforcement Action, Licensee shall consult in good faith with Licensor. <a name="z_Hlk127545280"></a>Licensee shall not compromise or settle any such enforcement
            action in a way that (i) could reasonably be expected to affect the validity or enforceability of any Licensed Patents, (ii) change the scope of the claims of any Licensed Patents, or (iii) result in an admission of liability on the part of
            Licensor, in each case, without Licensor&#8217;s prior written consent. All costs and expenses associated with enforcing the Licensed Patent in any such action will be borne by Licensee. Licensor will, at Licensee&#8217;s cost and expense, cooperate and
            provide reasonable assistance in any action described in this <font style="font-family: 'Times New Roman';"><u>Section 8.4.2.1</u></font>. Except for providing such cooperation and reasonable assistance, Licensor will have no
            obligation regarding the legal actions described herein; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided that</u></font> if required to enable Licensee to initiate or continue such action, Licensor will
            join such action at Licensee&#8217;s request and expense, or allow where required by law for Licensee to proceed in Licensee&#8217;s name. Any recovery or compensation resulting from such proceeding will first be used to reimburse Licensor for any
            unreimbursed expenses incurred in connection with providing assistance or joining the proceeding at Licensee&#8217;s request, and thereafter to reimburse Licensee for any other unreimbursed expenses incurred in connection with the proceeding
            (including attorneys&#8217; fees, expert witness fees, court fees, and related charges), and the remainder, if any, will be considered Sublicense Fees and shared between Licensee and Licensor in accordance with <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font>.</font></font></div>
      <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">If Licensee
            does not, within a reasonable period after becoming aware of a third party infringement of the Licensed Patents in the Field, but in any event no less than ninety (90) calendar days from becoming aware of the third party infringement, (i)
            initiate legal proceedings against such threatened or actual infringement, or defend legal proceedings brought by a third party, as provided in <font style="font-family: 'Times New Roman';"><u>Section 8.4.2.1</u></font> above, or
            (ii) take other reasonable steps to cause such infringement to terminate (for example, by initiating licensing discussions), Licensor may deliver written notice to Licensee that it intends to take action to cause such infringement to terminate,
            and subject to consultation with Licensee, Licensor may take such action as it deems reasonably necessary to enforce its rights in the Licensed Patents in the Field, including, without limitation, to bring, at its own expense, an infringement
            action or file any other appropriate action or claim related to such infringement against any third party. Licensee will, at the reasonable request of Licensor, cooperate and provide reasonable assistance in any action taken by Licensor and
            described in this <font style="font-family: 'Times New Roman';"><u>Section 8.4.2.2</u></font> and, if required to enable Licensor to initiate or continue such action, will join such action at Licensor&#8217;s reasonable request, all at
            Licensor&#8217;s cost and expense. Any recovery or compensation resulting from such proceeding undertaken by Licensor will first be used to reimburse Licensee for any unreimbursed expenses in connection with providing assistance or joining the
            proceeding at Licensor&#8217;s request, and thereafter to reimburse Licensor for any other unreimbursed expenses incurred in connection with the proceeding (including attorneys&#8217; fees, expert witness fees, court fees, and related charges), and the
            remainder, if any, will be retained solely by Licensor.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126327030"></a><font style="font-family: 'Times New Roman';">8.5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Infringement of Third-Party Rights</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.5.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Each Party will
            promptly notify the other Party in writing of any notice or claim of any allegation of infringement or commencement against it of any suit or action for infringement of a third-party patent based upon or arising from actions taken under the
            licenses granted in this Agreement (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Third-Party Infringement Claim</u></font>&#8221;). If such Third-Party Infringement Claim is alleged or commenced against Licensee,
            Licensee will have the sole right to defend and settle such Third-Party Infringement Claim, and Licensee will not be obligated to enter into negotiations with such third party to obtain rights for either Licensee or Licensor under the
            third-party patent. Subject to, and without limiting <font style="font-family: 'Times New Roman';"><u>Section 9.1</u></font>, if such Third-Party Infringement Claim is alleged or commenced against Licensor, Licensor will have the
            first right, but not the obligation, to defend and settle such Third-Party Infringement Claim,<font style="font-family: 'Times New Roman'; color: rgb(255, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that Licensor will not be obligated to enter into negotiations with such third party to obtain rights for Licensee under the third-party patent. With respect to any such defense by
            Licensee of a Third-Party Infringement Claim alleged or commenced against Licensee, Licensee will not make any settlements of such Third-Party Infringement Claim that would materially adversely affect Licensor&#8217;s rights or interests in the
            Licensed Patents without first obtaining Licensor&#8217; prior written consent, not to be unreasonably withheld or delayed. In any defense of a Third-Party Infringement Claim under this <font style="font-family: 'Times New Roman';"><u>Section
                8.5</u></font>, the non-defending Party will reasonably cooperate with the defending Party in the defense of such Third-Party Infringement Claim, including by cooperating with the defending Party in the assessment of such Third-Party
            Infringement Claim and, if requested by the defending Party, by assisting such defending Party in the development and evaluation of any available defense(s) in response to such Third-Party Infringement Claim based on the invalidity and/or
            non-infringement of the subject third-party patent(s). Subject to, and without limiting <font style="font-family: 'Times New Roman';"><u>Section 9.1</u></font>, the non-defending Party shall bear the cost of its cooperation in any
            such defense of a Third-Party Infringement Claim. Additionally, if in Licensee&#8217;s reasonable opinion, a Licensed Product is likely to become the subject of a Third-Party Infringement Claim, upon Licensee&#8217;s reasonable request therefor, Licensor
            shall in good faith assist Licensee in the assessment of the subject third-party patent(s) and the development of any bases of invalidity and/or non-infringement of such third-party patent(s), subject to Licensee&#8217;s reimbursement of any costs
            and expenses incurred by Licensor in connection therewith.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126325598"></a><font style="font-family: 'Times New Roman';">8.6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidential Information</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party shall maintain the Confidential Information of the other Party in strict confidence, and will not disclose, divulge or
        otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, or with the express written consent of the Party who provided such
        Confidential Information. Each Party will maintain the confidentiality of the other Party&#8217;s confidential information using methods and practices that are substantially similar to those that the receiving Party uses to maintain the confidentiality
        of its own confidential information, but in no event less than a reasonable degree of care. Except as may be authorized in advance in writing by the disclosing Party, the receiving Party will only grant access to the Confidential Information to its
        employees and agents as necessary to carry out activities under this Agreement and such employees and agents will have entered into non-disclosure agreements consistent with the terms of this <font style="font-family: 'Times New Roman';"><u>Section
            8.6</u></font>. The obligations of confidentiality described above will not pertain to that part of any Confidential Information to the extent that it is supported by competent written proof that:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">such information
            was lawfully in the receiving Party&#8217;s possession or control prior to the time it received the information from the disclosing Party;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.2</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">such information was
            developed by the receiving Party independently of and without reference to the Confidential Information of the disclosing Party;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.3</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">such information
            was, at the time it was disclosed to or obtained by the receiving Party, or thereafter became, available to the public through no act or omission of the Party holding such information; or</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">such information
            was lawfully obtained by the receiving Party from a third party that has the right to disclose such information free of any obligations of confidentiality.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In addition, a
            receiving Party may disclose such Confidential Information to the limited extent required to do so by Applicable Law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security
            issued by either Party is traded, or included in any filing or action taken by the receiving Party to obtain or maintain government clearance or approval to market a subject Licensed Product. Except where impracticable, such required Party
            shall give the other Party reasonable advance notice of such disclosure requirement and shall afford the other Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is
            impracticable to give an advance notice, such required Party shall give the other Party reasonable notice promptly after such required disclosure. In the event of any such required disclosure, the required Party shall disclose only that portion
            of the Confidential Information legally required to be disclosed.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In addition, either Party may disclose Confidential Information, including this </font>Agreement, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and the terms hereof (</font>including <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">providing a copy hereof, redacted as appropriate) to any bona fide potential licensor, licensee, partner or permitted
              Sublicensee </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">successor to said </font>Party<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s interest under this </font>Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, to a bona fide potential lender from which said Party is considering borrowing money, to a bona fide potential collaborator in connection with development </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">commercialization of </font>Licensed Products<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, to any bona fide financial investor from which
              said Party may take money, to any insurance broker, business, financial or scientific consultants, attorneys, and accountants; </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>provided,
                however</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, in any such case said Party shall first obtain a written obligation of confidentiality no less stringent than that imposed in this <u>Section </u></font><font style="font-family: 'Times New Roman';"><u>8.6</u></font> (or in the case of attorneys or other professionals, an equivalent
            professional duty of confidentiality) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">from the bona fide potential licensor, licensee, partner, permitted Sublicensee </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">successor, bona fide potential lender, bona fide potential collaborator, bona fide financial investor, insurance broker, business, financial or scientific consultant, attorney or accountant.</font></font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
          </font></font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">8.7</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Use of Names</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Neither Party may identify the other Party in any promotional advertising or other promotional materials to be disseminated to the public
        or any portion thereof, or use the name of any staff member or employee of the other Party or any trademark, service mark, trade name, symbol or logo that is associated with the other Party, without the other Party&#8217;s prior written consent.
        Notwithstanding the foregoing, and for the avoidance of doubt, without the consent of the other Party either Party may comply with disclosure requirements of all Applicable Laws relating to its business, including, without limitation, United States
        and state securities laws. Each Party may include the other Party&#8217;s name, logo, and a brief description of such other Party on said Party&#8217;s website.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Press Releases</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Parties shall mutually agree upon the timing and content of any press releases or other public announcement relating to this Agreement
        and the transactions contemplated herein.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref126326250"></a>Section 9</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Indemnification; Insurance</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref126326223"></a><font style="font-family: 'Times New Roman';">9.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Indemnification by Licensee</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee will
            indemnify, defend and hold harmless Licensor, its Affiliates and their respective directors, officers, employees, consultants, Licensor and agents, and their respective successors, heirs, and assigns (each a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensor Indemnitee</u></font>&#8221;), against all third party suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative
            expenses, and reasonable attorneys&#8217; fees), including claims resulting from or connected to the death of or injury to any person or persons, or any damage to property, resulting from, arising out of, or otherwise attributable to Licensee&#8217;s or,
            as applicable Licensee&#8217;s Affiliate&#8217;s or Sublicensee&#8217;s: (a) negligence or misconduct, (b) failure to comply with Applicable Laws or the terms of this Agreement, including any breach of Licensee&#8217;s express representations and warranties set forth
            in this Agreement, or (c) Exploitation of Licensed Products or the exercise of the licenses granted under this Agreement, including the sublicensing, production, manufacture, sale, use, lease, consumption, administration, shipping, storage,
            transfer, advertisement, analysis, measurement, description, or characterization of the Licensed Patents or Licensed Products, or any activity arising from or in connection with any right or obligation of Licensee hereunder, except in each case
            to the extent resulting from, arising out of, or otherwise attributable to Licensor&#8217;s failure to comply with Applicable Laws or the terms of this Agreement, including any breach of any express representation, warranty or covenant set forth in
            this Agreement, or any act of gross negligence or intentional misconduct by Licensor Indemnitee.</font></font></div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor will
            promptly give notice to Licensee of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might be covered by this <font style="font-family: 'Times New Roman';"><u>Section 9.1</u></font>
            and Licensee will have the right to defend the same, including selection of counsel and control of the proceedings; provided that Licensee will not, without the written consent of the applicable Licensor, settle or consent to the entry of any
            judgment with respect to any such third party claim (x) that does not release the applicable Licensor Indemnitee(s) from all liability with respect to such third party claim or (y) which may materially adversely affect Licensor or the Licensor
            Indemnitees or under which such Licensor or the applicable Licensor Indemnitee(s) would incur any obligation or liability, other than one as to which Licensee has an indemnity obligation hereunder. Licensor agrees to fully cooperate and aid
            such defense. Licensor at all times reserve the right to select and retain counsel of its own at its own expense to defend such Licensor&#8217;s interests.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-size: 10pt;"><a name="z_Ref45025783"></a><font style="font-family: 'Times New Roman';">9.2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Indemnification by Licensor</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.2.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor will
            indemnify, defend and hold harmless Licensee, its Affiliates and their respective directors, officers, employees, consultants, Licensor and agents, and their respective successors, and assigns (each a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee Indemnitee</u></font>&#8221;), against all third party suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and
            reasonable attorneys&#8217; fees) resulting from, arising out of, or otherwise attributable to Licensor&#8217;s (a) negligence or misconduct, or (b) failure to comply with Applicable Laws or the terms of this Agreement, including any breach of Licensee&#8217;s
            express representations and warranties set forth in this Agreement, except to the extent resulting from, arising out of, or otherwise attributable to Licensee&#8217;s failure to comply with Applicable Laws or the terms of this Agreement, including
            any breach of any express representation, warranty or covenant set forth in this Agreement, or any act of gross negligence or intentional misconduct by a Licensee Indemnitee.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.2.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee will
            promptly give notice to Licensor of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might be covered by this <font style="font-family: 'Times New Roman';"><u>Section 9.2</u></font>
            and Licensor will have the right to defend the same, including selection of counsel and control of the proceedings; provided that Licensor will not, without the written consent of Licensee, settle or consent to the entry of any judgment with
            respect to any such third party claim (x) that does not release the Licensee Indemnitee(s) from all liability with respect to such third party claim or (y) which may materially adversely affect Licensee or the Licensee Indemnitee or under which
            Licensee or the Licensee Indemnitee would incur any obligation or liability, other than one as to which Licensor has an indemnity obligation hereunder. Licensee agrees to fully cooperate and aid such defense. Licensee at all times reserves the
            right to select and retain counsel of its own at its own expense to defend Licensee&#8217;s interests.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Insurance</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall maintain in full force and effect during the
        </font>Term <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and for a </font>period of three (3) years <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">after expiration </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">termination of this </font>Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, worker&#8217;s compensation, general liability and professional
          liability, clinical trial liability, and product liability insurance coverage, all in such amounts and with such scope of coverages as are reasonably sufficient to </font>cover Licensee<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s obligations under this </font>Agreement <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(</font>including Licensee<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s
          indemnity obligations set forth in <u>Section 9.1</u></font>) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and as are customary
          in the life sciences and pharmaceutical industries. Upon written request, </font>Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall provide evidence of such insurance to </font>Licensor<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. </font>Licensor <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall be named as an additional insured with respect to such insurance
          policies, and </font>Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall ensure that </font>Licensor <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">will receive no less
          than fourteen (14) days&#8217; prior notice of any cancelation, non-renewal </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">material change in such insurance coverage.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 10</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><a name="z_Ref126326300"></a><font style="font-family: 'Times New Roman';"><u>Alternative Dispute Resolution</u></font></div>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126327134"></a>10.1.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Negotiation</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;">In the event of any dispute or disagreement between Licensor and Licensee as to the interpretation of any provision of this Agreement or
        any other related document (or the performance of any obligations hereunder or thereunder), the matter, upon written request of either Licensor or Licensee, shall be referred to representatives of Licensor and Licensee for decision, each such Party
        being represented by an Executive Officer (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representatives</u></font>&#8221;). The Representatives shall promptly meet and use good faith efforts to resolve the dispute.
        If the Representatives do not mutually agree upon a decision within <a name="OLE_LINK1"></a>thirty (30) calendar days (as extended by the last sentence of this <font style="font-family: 'Times New Roman';"><u>Section 10.1</u></font>)
        after reference of the matter to them, <a name="z_Hlk62229994"></a>the Parties shall submit to mediation by a single independent mediator, with expertise and experience applicable to the subject matter of the dispute, mutually agreeable to the
        Parties and in accordance with procedures as may be mutually agreed in writing by the Parties. If the dispute is not resolved pursuant to such mediation (including if the Parties are unable to mutually agree on the selection of a mediator or the
        relevant procedures for such mediation), then each of the Licensor and Licensee shall be free to exercise the remedies available to it under <font style="font-family: 'Times New Roman';"><u>Section 10.2</u></font>. Each of the Licensor
        and Licensee may extend the period of time for negotiation among the Representatives for an additional period of thirty (30) calendar days on one (1) occasion per dispute.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Hlk39070081"></a><a name="z_Ref126327139"></a>10.2.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Submission to Arbitration</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If the Licensor and Licensee are unable to resolve such dispute pursuant to <font style="font-family: 'Times New Roman';"><u>Section
            10.1</u></font>, the dispute shall be submitted to binding arbitration (without any recourse to the federal or state courts except to enforce any arbitral award or, within forty five (45) days of an Arbitrator&#8217;s rendering of a final decision,
        to appeal such final decision based solely on a claim that the Arbitrator engaged in gross misconduct or made a material error or miscalculation in his or her decision) in accordance with the rules of JAMS (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>JAMS</u></font>&#8221;) then in force (except as expressly modified below), and the arbitration hearings shall be held before a single arbitrator (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Arbitrator</u></font>&#8221;) in Boston, Massachusetts. The Licensor and Licensee agree to appoint an Arbitrator who is knowledgeable in the biotechnology and/or life sciences industries. If the Licensor and Licensee cannot
        agree upon an Arbitrator within ten (10) days after a demand for arbitration has been filed with the JAMS by either of them, either or both of the participating Licensor and Licensee may request the JAMS to name a panel of five (5) candidates to
        serve as Arbitrator. The participating Licensor and Licensee shall each, in successive rounds (with the Party demanding the arbitration having the first chance to strike a name), strike one name off this list until only one name remains, and such
        last-named person shall be the Arbitrator.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.3.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Conduct of Arbitration</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Arbitrator shall be required to (a) follow the substantive rules of Massachusetts State or Federal law, as applicable, (b) have all
        testimony be transcribed, and (c) accompany his or her award with findings of fact and a statement of reasons for the decision. The Arbitrator shall have the authority to permit discovery for no more than thirty (30) days, to the extent deemed
        appropriate by the Arbitrator, upon reasonable request of a participating Party. The Arbitrator shall have no power or authority to (i) add to or detract from the written agreement of the Parties set forth herein, (ii) modify or disregard any
        provision of this Agreement or any of the other related documents, or (iii) address or resolve any issue not submitted by the Parties. The Arbitrator shall hold proceedings during a period of no longer than thirty (30) calendar days promptly
        following conclusion of discovery, and the Arbitrator shall render a final decision within thirty (30) days following conclusion of the hearings. The Arbitrator shall have the power to grant injunctive relief (without the necessity of a Party
        posting a bond) in the event a Party has violated the confidentiality provisions set forth in this Agreement, but shall have no power to award punitive and/or exemplary damages in the event of a breach. In the event of any conflict between the
        commercial arbitration rules then in effect and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.4.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Interim Relief</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Either Licensor or Licensee may, without waiving any remedy under this Agreement, apply to the Arbitrator for interim injunctive relief
        until the arbitration award is rendered or the controversy is otherwise resolved. Either Licensor or Licensee also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief
        necessary to protect the rights regarding the Intellectual Property or Confidential Information of that Party pending the arbitration award. The Arbitrator shall have no authority to award punitive or any other type of damages not measured by a
        Party&#8217;s compensatory damages.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.5.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Cost of Arbitration</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Licensor and Licensee shall share in the actual and direct costs of the engagement of the Arbitrator, but the prevailing Party(ies) in
        the arbitration shall be reimbursed by the non-prevailing Party(ies) for the prevailing Party&#8217;s fees and costs of arbitration (e.g., the costs, fees and expenses of outside experts and counsel retained by the prevailing Party). If Licensor or
        Licensee is not deemed by the Arbitrator to be the primary prevailing Party, then each Party will pay its own costs, fees and expenses (including attorneys&#8217; fees) and an equal share of the Arbitrator&#8217;s fees and any administrative fees of
        arbitration.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126327305"></a>10.6.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Excluded Claims</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Unless otherwise mutually agreed upon by the Parties in writing, any Excluded Claims shall be brought in the federal court for the
        District Court of Massachusetts, if federal jurisdiction is available, or, alternatively, in the state courts in Suffolk County, Massachusetts. Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any
        such litigation; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on
        the judgment or in any other manner provided by law. Each Party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such
        litigation brought in any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation. As used in this <font style="font-family: 'Times New Roman';"><u>Section
            10.6</u></font>, the term &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Excluded Claim</u></font>&#8221; means a dispute, controversy or claim that concerns: (x) the scope, construction, validity or infringement of a
        patent, trademark or copyright; or (y) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory; or (z) the Licensee&#8217;s or, as applicable Licensee&#8217;s Affiliates or Sublicensee(s), Exploitation of Licensed Products or
        use of the Licensed Patents outside of the Field.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.7.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Injunctive Relief; Specific Performance</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding anything to the contrary herein, nothing in this <font style="font-family: 'Times New Roman';"><u>Section 10</u></font>
        shall preclude a Party from seeking injunctive relief or specific performance in a court of competent jurisdiction.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.8.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidentiality</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an Arbitrator may disclose the
        existence, content, or results of the arbitration without the prior written consent of the other Parties, except to its directors and officers. In no event shall arbitration be initiated after the date when commencement of a legal or equitable
        proceeding based on the dispute, controversy or claim would be barred by the applicable Massachusetts statute of limitations.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 11</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Miscellaneous</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.1.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Compliance with Law</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with performing its obligations or exercising its rights under this Agreement, Licensee agrees to comply with all Applicable
        Laws. Without limiting the foregoing, by entering into this Agreement, the Parties specifically intend to comply with, and require its Sublicensees complies with, all Applicable Laws, including, if applicable, such laws pertaining to Licensed
        Products, including (i) the federal anti-kickback statute (42 U.S.C. &#167;1320a-7b) and the related safe harbor regulations; and (ii) the Limitation on Certain Physician Referrals, also referred to as the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Stark Law</font>&#8221; (42 U.S.C. &#167;1395nn). Accordingly, no part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or
        services; nor are the payments intended to induce illegal referrals of business.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126325477"></a>11.2.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Assignment</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement will be binding upon and will inure to the benefit of each Party and each Party&#8217;s respective transferees, successors and
        assigns, pursuant to the provisions set forth below. Licensee may not transfer or assign this Agreement without the prior written consent of Licensor, except as provided in this <font style="font-family: 'Times New Roman';"><u>Section
            11.2</u></font>. In the event that a third party (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Acquiring Party</u></font>&#8221;) acquires all or substantially all of Licensee&#8217;s business, capital stock or
        assets, whether by sale, merger, change of control, operation of law or otherwise (an &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Acquisition</u></font>&#8221;), the rights granted to Licensee under this Agreement
        pertaining to any and all Licensed Patents shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition, the Acquiring Party will be responsible for all payments and other obligations set forth in
        this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition, and payment thereof shall remain an ongoing obligation of the Acquiring Party until
        such amount is paid in full. Any attempted assignment in contravention of this <font style="font-family: 'Times New Roman';"><u>Section 11.2</u></font> will be null and void.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126327199"></a>11.3.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Entire Agreement</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter thereof and supersedes all
        previous negotiations, commitments, and writings with respect to such subject matter. Licensor, Brooklyn and Licensee hereby terminate the Prior Agreement (including Section 2A of the Prior Agreement), subject to applicable provisions in such
        agreements surviving as specified therein, provided that notwithstanding anything to the contrary herein or in the Prior Agreement, Licensor, Brooklyn and Licensee hereby agree that Section 2A.10.4 of the Prior Agreement is terminated, and hereby
        superseded and replaced in its entirety by the applicable terms of this Agreement. The Parties hereby acknowledge and agree that the Prior Agreement, and all rights, obligations and licenses of each of the Parties under the Prior Agreement, shall
        be deemed to be superseded in all respects as of the Effective Date by this Agreement; provided that any dispute or alleged breach by a Party of any of the terms of the Prior Agreement during the period that the Prior Agreement was in effect shall
        be governed solely by the terms of the Prior Agreement and the terms and conditions of the Prior Agreement shall survive solely for the limited purpose set forth in this <font style="font-family: 'Times New Roman';"><u>Section 11.3</u></font>.
        <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither </font>Party shall <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">be obligated by any undertaking </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">representation regarding that subject matter other than those expressly stated herein </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">as
          may be subsequently agreed to by the Parties hereto in writing.</font> In the event of any conflict or inconsistency between any provision of any Exhibit hereto and any provision of this Agreement, the provisions of this Agreement shall prevail.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.4.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Amendment</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed
        by a duly authorized officer of each Party.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126327207"></a>11.5.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Notices</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will be deemed to have been given at
        the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, facsimile or electronic transmission, including PDF (portable document format), delivery
        by a professional courier service or delivery by first class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or at such changed address as the Party will have specified by written
        notice in accordance with this <font style="font-family: 'Times New Roman';"><u>Section 11.5</u></font>; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that any notice of
        change of address will be effective only upon actual receipt.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If to </font><font style="font-size: 10pt;">Licensor<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">:</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Factor Bioscience Limited</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">c/o Factor Bioscience Inc.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Attn: </font><font style="font-size: 10pt;">Christopher Rohde, Ph.D., Chief Technology Officer</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 17B</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cambridge, MA 02141</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">chris.rohde@factorbio.com</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With copy to which shall not constitute notice:</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Morgan, Lewis &amp; Bockius LLP</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Stephen L. Altieri, Ph.D., J.D.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">One Federal Street</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Boston, MA 02110-1726</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">stephen.altieri@morganlewis.com</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If to Licensee:</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Eterna Therapeutics, Inc.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Andrew Jackson, Chief Financial Officer</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 18A</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cambridge MA 02141</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">andrew.jackson@eternatx.com</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With copy to which shall not constitute notice:</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Goodwin Procter LLP</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">New York Times Building</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">620 8th Ave, New York, NY 10018</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Lily Wound, Esq</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">LWound@goodwinlaw.com</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.6.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Governing Law</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The substantive law governing this Agreement (which shall be applied in the arbitration) shall be, with respect to disputes involving
        general contract or trade secret matters, the internal laws of the state of New York, and with respect to matters involving patents, the United States Patent Act, as to copyright matters, the United States Copyright Act, and as to trademark
        matters, the United States Trademark Act, each as amended from time to time. Any award rendered by the Arbitrator shall be final, conclusive and binding upon the Parties to this Agreement, and judgment thereon may be entered and enforced in any
        state or federal court of competent jurisdiction.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.7.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Descriptive Headings</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in
        this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. Licensee hereby acknowledges that Licensor owns and/or has in-licensed the Licensed Patents, and the use of
        the term &#8220;license&#8221; hereunder with reference to the rights granted to Licensee is understood by the Parties to mean either a direct license of Licensor&#8217;s ownership interest in the subject Licensed Patent or a sublicense of Licensor&#8217;s in-licensed
        interest in the subject Licensed Patent, as applicable. The headings of each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the
        particular Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense (and/or). The term &#8220;including&#8221; as used herein means including, without
        limiting the generality of any description preceding such term.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.8.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Independent Contractors</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensor and Licensee are independent contractors under this Agreement. Nothing contained in this Agreement will be deemed to create an
        employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other
        Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126327241"></a>11.9.&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Severability</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The illegality or partial illegality of any provision of this Agreement will not affect the validity of the remainder of this Agreement,
        or any provision thereof, and the illegality or partial illegality of any provision of this Agreement will not affect the validity of this Agreement in any jurisdiction in which such determination of illegality or partial illegality has not been
        made, except in either case to the extent such illegality or partial illegality causes this Agreement to no longer contain all of the material provisions reasonably expected by the Parties to be contained therein. Moreover, in the event that a
        court of competent jurisdiction determines that any provision of this Agreement is illegal or partially illegal, then it is the intention of the Parties that such provision be modified to the minimum extent deemed necessary by such court to make
        such provision enforceable and to give effect to the original intention of the Parties.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.10.&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Waiver of Compliance</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The failure of either Party to comply with any obligation, covenant, agreement or condition under this Agreement may be waived by the
        Party entitled to the benefit thereof only by a written instrument signed by the Party on granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition will not operate as a
        waiver of, or estoppel with respect to, any subsequent or other failure. The failure of any Party to enforce at any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way to
        affect the validity of this Agreement or any part thereof or the right of any Party thereafter to enforce each and every such provision. No waiver of any breach of such provisions will be held to be waiver of any other or subsequent breach.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.11.&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Counterparts</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the
        signature of more than one Party but all such counterparts taken together will constitute one and the same agreement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.12.&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Authority</u></font>.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The persons signing on behalf of Licensor and Licensee hereby warrant and represent that they have authority to execute this Agreement on
        behalf of the Party for whom they have signed.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref126326267"></a>11.13.&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Non-Disparagement</u></font>.</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee on behalf of itself, its Affiliates and Sublicensees hereby covenants and agrees that it shall not make, write or publish any
        statement, assertion or claim that disclaims, disparages, denies, questions or otherwise challenges or casts doubt upon the validity, enforceability, scope, construction or inventorship of any patent Controlled by Licensor (including, but not
        limited to, any pending or issued claim(s) within the Licensed Patents). The provisions set forth in this <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font> shall take effect on the Effective Date, shall not
        require any further consideration or performance of Licensor, and shall survive the expiration or termination of this Agreement for five (5) years from the date or expiration or termination of this Agreement. If any part of this <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font> shall be deemed illegal or unenforceable by a court of competent jurisdiction, that part shall be deemed automatically deleted (or modified to the minimum extent deemed
        necessary by such court to make such provision enforceable and to give effect to the original intention of the Parties pursuant to <font style="font-family: 'Times New Roman';"><u>Section 11.9</u></font>), such deletion being made as
        narrowly as possible (and, if possible, only in said jurisdiction) to maintain, as much as possible, the intent of this <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font>, and the remainder of this <font style="font-family: 'Times New Roman';"><u>Section 11.13</u></font> shall, with related definitions, remain in full force and effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">11.14.&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Non-Solicitation</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;">During the Term, neither Licensor nor Licensee, without the prior written consent of the other Party, shall directly or indirectly
        solicit for employment any employee of the other Party or any of its Affiliates or subsidiaries, or any person who has terminated his or her employment with the other Party or any of its Affiliates or subsidiaries within the previous twelve
        (12)-month period prior to any purported solicitation; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided</u></font><font style="font-family: 'Times New Roman';"><u>, </u></font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>however</u>,</font> the foregoing will not prevent Licensor or Licensee from employing any
        such person who contacts such Party on his or her own initiative without any direct or indirect solicitation by or encouragement from the soliciting or hiring person. General advertising which is not directed at any specific employee of a Party
        will not be deemed solicitation, and hiring of employees of such Party which are solicited in this manner will not be a breach of this provision.</div>
      <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.15</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Force Majeure</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither </font><font style="font-size: 10pt; font-family: 'Times New Roman';">Party </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">hereto shall be liable for failures and delays in performance due to strikes, lockouts, fires,
          acts of God </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the public enemy, riots, incendiaries,
          interference by civil </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">military authorities, acts of domestic
          or international terrorism, endemic, pandemic, and the results related to such acts, compliance with the laws of various states/countries, </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">with the orders of any governmental authorities, delays in transit </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">delivery on the part of transportation companies, failures of communication facilities, </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any failure of sources of material. Notwithstanding the foregoing, if a Party is prevented from fulfilling its obligations
          under this Agreement for more than one hundred twenty (120) days due to such foregoing reasons, the other Party shall be entitled to immediately terminate this Agreement upon written notice.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>No Preferential Treatment, Fraudulent Conveyance, Insolvency</u></font>.</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.1</font><font style="font-size: 10pt;">&#160; <font style="font-family: 'Times New Roman';">The Parties have not
            entered into this Agreement to provide any preferential treatment under section 547 of title 11 of the United States Code, as amended (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Bankruptcy Code</u></font>&#8221;)
            or any other applicable insolvency law.</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.2</font><font style="font-size: 10pt;">&#160;&#160; <font style="font-family: 'Times New Roman';">Neither the
            execution or delivery of this Agreement or the consummation of the transactions hereunder were entered into with the intent by the Parties to effectuate a transaction that may be avoided under section 548(a) of the Bankruptcy Code, the Uniform
            Fraudulent Transfer Act (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>UFTA</u></font>&#8221;), the Uniform Voidable Transactions Act (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>UVTA</u></font>&#8221;)
            or any other applicable insolvency law. The Parties received reasonably equivalent value in exchange for the obligations provided hereunder. The transactions contemplated hereunder are not subject to avoidance under section 548(a) of the
            Bankruptcy Code, the UFTA, or any applicable insolvency law.</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.3</font><font style="font-size: 10pt;">&#160;&#160; <font style="font-family: 'Times New Roman';">As of the Effective
            Date, Licensor does not intend to file for protection or seek relief under title 11 of the Bankruptcy Code or any similar federal or state law providing for the relief of debtors. Licensor is not now insolvent (as such term is defined in the
            Bankruptcy Code or any other applicable law relating to insolvency).</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.4</font><font style="font-size: 10pt;">&#160;&#160; <font style="font-family: 'Times New Roman';">Notwithstanding any
            other provision of this Agreement to the contrary, in the event that Licensor becomes a debtor under the Bankruptcy Code and rejects this Agreement pursuant to section 365 of the Bankruptcy Code (a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Bankruptcy Rejection</u></font>&#8221;): (a) any and all of the licensee and Sublicensee rights of Licensee arising under or otherwise set forth in this Agreement, shall be deemed fully retained by and vested in
            Licensee as protected intellectual property rights under section 365(n)(1)(B) of the Bankruptcy Code and further shall be deemed to exist immediately before the commencement of the bankruptcy case in which such Licensor is the debtor; (b)
            Licensee shall have all of the rights afforded to non-debtor licensees and Sublicensees under section 365(n) of the Bankruptcy Code and all other applicable laws; and (c) to the extent any rights of Licensee under this Agreement that arise
            after the termination or expiration of this Agreement are determined by a bankruptcy court to not be &#8220;intellectual property rights&#8221; for purposes of section 365(n), all of such rights shall remain vested in and fully retained by Licensee after
            any Bankruptcy Rejection as though this Agreement were terminated or expired. Licensee shall under no circumstances be required to terminate this Agreement after a Bankruptcy Rejection in order to enjoy or acquire any of its rights under this
            Agreement, but retains the right to do so in accordance herewith.</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Remainder of page intentionally left blank.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Exclusive License Agreement as of the Effective Date.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z8e32c795ee69483892b12f5ce4e671fa" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">Factor Bioscience Limited</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic; margin-left: 18pt;">/s/ Christopher Rohde</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Christopher Rohde, PhD</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Chief Technology Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">Eterna Therapeutics Inc.</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic; margin-left: 18pt;">/s/ Andrew Jackson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Andrew Jackson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><a name="z_Hlk126324904"></a>Chief Financial Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">Eterna Therapeutics LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic; margin-left: 18pt;">/s/ Andrew Jackson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Andrew Jackson</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Manager &amp; Chief Financial Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;"><br>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>erna-20230220.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.1.2.5118 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20230220" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20230220" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20230220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20230220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>erna-20230220_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.1.2.5118 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>erna-20230220_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.1.2.5118 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20230220.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139931366712672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 20,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10531 4S COMMONS DRIVE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 166-550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">SAN DIEGO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10048628_form8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20230220.xsd" xlink:type="simple"/>
    <context id="c20230220to20230220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2023-02-20</startDate>
            <endDate>2023-02-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230220to20230220"
      id="Fact_25044cef1f56455e9578189b3aab123e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230220to20230220"
      id="Fact_0458c2ed6e6840d7ae8396e06eb93d45">0000748592</dei:EntityCentralIndexKey>
    <dei:EntityAddressAddressLine1
      contextRef="c20230220to20230220"
      id="Fact_86f951afb78c444b86079efd2ccf8734">10531 4S COMMONS DRIVE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230220to20230220"
      id="Fact_d8c25c8fcc084b0582604d96e1ec64d0">SUITE 166-550</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230220to20230220"
      id="Fact_e6278cb7aa0243eb93f119f7f0d167ca">SAN DIEGO</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230220to20230220"
      id="Fact_16c491966e0d449c8689f3e36f86b228">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230220to20230220"
      id="Fact_fcf56aabc71a49178f7e9341812b09e6">92127</dei:EntityAddressPostalZipCode>
    <dei:DocumentType
      contextRef="c20230220to20230220"
      id="Fact_52c60337ab5e4a4f86427b509dac6c3e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230220to20230220"
      id="Fact_3b33c81a345846b681d417c9ec26382d">2023-02-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230220to20230220"
      id="Fact_af5a345f321c4f55a34abd8e3991156b">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230220to20230220"
      id="Fact_3c23910a780f4b518dd71a121ab3f547">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230220to20230220"
      id="Fact_26f65c3179fe41a09af7afd50ac96c68">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230220to20230220"
      id="Fact_143bd59d435c4575afdcdaeb2b4ed962">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="c20230220to20230220"
      id="Fact_c6c63efb39b542549a4e8522e86ee033">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230220to20230220"
      id="Fact_533083fa238448f1873c0a4dae4ddb48">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230220to20230220"
      id="Fact_5dcb4438ac0c49eeb9cd342c7eb6cff5">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230220to20230220"
      id="Fact_2be114314a874ca6867aa1f784dc34a7">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230220to20230220"
      id="Fact_efa4b15ea50549a0822b56244fc35df3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230220to20230220"
      id="Fact_c83de09426674aa0b34095ffed9071bc">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230220to20230220"
      id="Fact_9340d16c8e8b4392bd2bd6f33b18feb4">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230220to20230220"
      id="Fact_621e6a01ca6c45a1aae35dbd2a3e7ef2">ERNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230220to20230220"
      id="Fact_7d6d984c12114c35b0c14db2d6093a02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230220to20230220"
      id="Fact_e708b419a44d4721a800fd2ed4a6c5c3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ):+5E8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "6BU96YZVYX^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OITU%)'1S43PI""XHWD(RNQML_I",M/OVMG&WB^@#>,S,+]]\
M ]/K*'1(^)Q"Q$06\]7D!I^%CAMV((H"(.L#.I7K.>'GYBXDIVA^ICU$I3_4
M'H$WS0TX)&44*5B 55R)3/9&"YU044@GO-$K/GZFH<",!AS0H:<,;=T"D\O$
M>)R&'BZ !4:87/XNH%F)I?HGMG2 G9)3MFMJ',=Z[$INWJ&%MZ?'E[)N97TF
MY37.O[(5=(RX8>?)K]W=_?:!2=[PKFIXQ?F6<\%OQ77[OKC^\+L(NV#LSOYC
MX[.@[.'77<@O4$L#!!0    ( ):+5E:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MEHM65N#_Z&9Q!   0Q$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF'UOZC84QK^*E4W3)K4E#B^%#I HT#MT;REKN/=*F_:'20Q83>)<VX'VV^\X
MT(1UX81*E#BQG_Q\?/*<F/Y>JA>]Y=R0USA*],#9&I/>-1HZV/*8Z1N9\@2N
MK*6*F8&FVC1TJC@+\T%QU/!<M].(F4B<83\_MU##OLQ,)!*^4$1G<<S4VSV/
MY'[@4.?]Q+/8;(T]T1CV4[;A/C=?TX6"5J-0"47,$RUD0A1?#YP1O;OWVG9
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M&H[@??<\"BX )!A(62XH[O-?9  Q66QE@M6O&I%VUP,3Z?4PHK(Z4-S4E\)
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ EHM65I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "6BU96
M'#AEZC\!   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^0!-0
MBU1$N)0^D*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q']>5=
M2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9
M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
MEHM65B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ EHM65@=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "6BU96YZVY
MX^T    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "6BU96F5R<(Q &  "<)P  $P              @ '+ 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ):+5E;@_^AF<00  $,1
M   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "6BU96GZ ;\+$"  #B#   #0              @ &S#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ):+5E:7BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10048628_form8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressAddressLine1, dei:EntityAddressAddressLine2, dei:EntityAddressCityOrTown, dei:EntityAddressPostalZipCode, dei:EntityAddressStateOrProvince -  brhc10048628_form8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="brhc10048628_form8k.htm">brhc10048628_form8k.htm</File>
    <File>brhc10048628_ex10-1.htm</File>
    <File>erna-20230220.xsd</File>
    <File>erna-20230220_lab.xml</File>
    <File>erna-20230220_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10048628_form8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10048628_form8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20230220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20230220_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "erna-20230220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 7
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20230220",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10048628_form8k.htm",
      "contextRef": "c20230220to20230220",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10048628_form8k.htm",
      "contextRef": "c20230220to20230220",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-23-008076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-008076-xbrl.zip
M4$L#!!0    ( ):+5E9^0J"ASH@  (M6 P 7    8G)H8S$P,#0X-C(X7V5X
M,3 M,2YH=&WLO6MSV\J5-OK]5)W_@),Y,Z]412NZ6):]G4F]VK:<K1EOVT>2
MD\FG*9!L2HA!@ . DIE??]:MNU<W0$JBH)M?IV82BP31]]7K\JQG_>FBF>9_
M_K__KR3YTX5)Q_0O^'>3-;GY\Y_^R/\K'_X_+UXD'[.1*6HS3IKRE^37JDS'
M538^-\F'K$B+49;FR6F9SYNL+.I!\O'C._XI_>=].9I/3=$DH\JD#;QB7F?%
MN7[)EY//DRPWR>[>UL[6[M;^SLYK]?MWY6Q19><73;+SYLU^\B+9W=[=TS]_
M\8('\D<9R9^&Y7B1#,]'95Y6__Z'?YG0?_Z0U,TB-__^ATE9-"\FZ33+%[\D
M_^LLFYHZ^62NDI-RFA;_ZVU"W]?9/\TOR<[VK'F;-.9[\R+-L_/BER0W$_B$
MWOQ+\B_;])^W?^#V\8=!(^HE\L@?\7/^YSB[M!-\425%65^D8_BA_.,/"37X
M[W^ :6],Y3I_87 F?DE>SKZWNI$,T]&W\ZJ<%^,7\5=Z#/S*M\DTK<ZSX@4.
MZ9<DG3>E^ZCB1OBS85F-#;RK* LCXPBZSW_8#NJ&Z#4RH;>9</K@2D8Z+/,Q
M-/NG-"G2*33PS__^+?^VL_MJ;_?EF^T]^.*/:>O+@Y?[>V_V=_C+H^\7V3"#
MW;.]M?.G/R[K=WO!_C2L_)-+?]<UL;<=,+0U__/1?[W[^/7T^*]'R<?C=T>?
M3H^2P[^<'!W]?O3I[$]_G/_Y?GO^CWG=9).%[).L&,-(?DGV7LW66+X__/GL
MM^/39,5XDHWF(JN3?_N7U[N[VV_;Y^;:QO#97Y*L@=Z/>/8.SRMC4,KP7-$Q
MH_?OO-WTL@0:I24"(90539FD=5).$NK,!S.LYFFU .DR8 D#G32]]O%H,C&C
M)KLTR7N0@QT='23#19(6XV1HFBMCBN1#.FK**ODU*^M19HJ1 3D\S4"&#I(4
M3O]TEA:+I*S.TP*F?TP_-=\S6$J0KR %3)7@&/+TJO9S  ,^KDR.SV[T.3J^
M(<JJ<US8VA%,?)$F9Q>F2F<&[HI1G1P7HRT>2S4KJQ3OCYN-A]?-)*<-3"7^
M\1Z&=)56YCX&9;H6:RNQ(Z9^VB=!A"X2DXXN8!&3RDQ,5=&M"1N.-YK;J? )
MG,9L/$_S?(%;,>UUMWU)JV;1[C=U%FZ'G+<BM]SW3L>V,U.KUK>D^><DQO[V
MV]')T>'I(%SHKFT,"D^R,?GCMS^FJ)>4W_)%D1Q/I_.B;*+'-OO=G[:U)8<N
M.9R 8I7)$;%;=)#,*G.9E?,:5C^4AT5R]'V4@X)V:>SC?L,Z\91.2SB0=E8&
M?LSXY:<2=A6\(IHAEEO]CMXVU3UZDA&'LRK+D]U7)--WZ%-0%&!CC'$PS44*
M:JFIFA1.YX>LJIOD$+^EXPGSL<YD^%GNG)9!,B8EF+KGI3)^/1V"@-O=I:[N
M)AN^JX/^#VB5P79>=6FNT4ZDL?W;O^R\@N[R:V$*GN71QXD7:99,YXW(:IPW
MW!^PPPUN(U--P0Z"4T:/AW.+@C]K2/'(*M,L^#*D8\>'+KP5X'#.JWJ>T@;T
M^^/J(H,KQ0DBL!'R/#FO\#%W\Y"Z76._[)9V5ML7Z%P!W]$EA%:;R<?VCS.X
MHC)0,Q:TY>HYM(,#@MT'M^G83+("7H CS8K-K>>TB)\^_VV0G.%*?OA\<C3
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MN1>DD%=C&N+"(VXD.$ JOG^!W'^$;OF?>59)"$)DG9T4N0II9M!8Z9J4YW>
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M8(Q0S?O([5%C=PA^PJ>B)% <FM4S7!G>NY,Y12-F#F6+42S\GSEFT<![865
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MUI$%23?X@!MO?:UBX L>\"AJ/RGM(U1KBV*U=K2L ^=@M1?RC%:,_$0]/C]
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M88#HP?[V>DB<O=LC<9X,!F<)H>_SP> 8<SO=J(5J7+)W??XU:^XK<#G^"$4
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M*>T<'7=ME;[0^K*%;^^EK<1SLG#? S7U+NQ@R9N(%ROK<TU1P^QP);>&?-,
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MS1I?8XSM4+_X3 C8<?+?/DPH[;Y7>&TTTQU7%1<RCNH+;:N5M;%4S3SQ:RX
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MFM.**Y:Z%FK;/9F,YQS?BH:]V<>9=![?6PK_@1?]#R#K!RO$8_=W6L@-5@J
MP1U/L3_$;,;:$]S2ZI^(<M\''6)H'R@+X<YC[(/5;DFO7V\=])?,_-B0C*\L
M9#ZETR7\7(_@UEL7C?&II;.SE.O.5B&, TBMLA$&:$0:-YP8HB6M>\"BDFMO
M=]>&$VW'H2]=A>,%2\'F/KOC4846N 5A'V'JG7.A22>39&JF0U:+;<RY"S$B
MKR:G&+JE!DEMJDOT;_!?] 6]';Y93(<EB9Z\/)<H;M9-#J6:\ FXRQ 1W?Q!
M?OB?R@9?@;@'QTCC:IFPJC+A*$627I89<V# 6,?E?-B$S4=P$#T3K65'+Z5
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ML9I9CXL96[0VRQR$A!,SN$^DL9[TK635$-.\+M<<)_S\FV#<24+/J\9:7_^
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MA&Z'CDZ:X4(<(K7W3Y%K $Y6T"^+W986G9#D NXMMAAZ%A-)SX6IM9<MZHJ
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MDNM6P\ ,K=^RAR++K+TY=;9AD;SCCB=?+A9U-H)M#T8,YOIQ-54,8>K<OY1
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M'C!A@%4DPKV485*+LEU8$J97!]09QUR.W;[B[5DB1WT01.09EL)2!,^R%$G
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M^(C2A/H)/9< $!&][BE?>)L:JKT22',I6QNI;QQ6N=EFYC7JEGI>UF)DAIA
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MB []YS^^?](O!M?XXGPZRLV+_P%02P,$%     @ EHM65O#/"Q1P%P  [(T
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M>4LF-+[UPPXZW4-"9VFT>!1GO<AGZ.Z;QHB\R@=9U\$V6$!#+" ?W.=C=*.
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MN@J#H-[5N*4X.E5:R,9:_(8VO=C=?T$33O]<E9S,_I"/-/XD4KQ7Y&6"DV=
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MR3 >ED-X%TC%XLGL23)!'9#;W:G[?!L\LLW P ,Q-HER"I<E#D[C94/7IW+
MN^ITKJ7,1 2)4 \>B+%N&*FWP/"9O:Q6S^ZZ4_$.Q]):7+%/_,V_15.8OREW
M]C]02P,$%     @ EHM65J> $!W;!0  \3X  !4   !E<FYA+3(P,C,P,C(P
M7W!R92YX;6S56]MNXS80?2_0?U#=9UN1W-UN@G@7J7>S,)I-C"1%+R\%+=$V
M48DT*#EV_KZD3"8615)R+HO)BR^:P^$9GJ/;6#[]M,VSX [S@C ZZD6#HUZ
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MH;VH3BZPIM']'<AM.A?]N*,%XHX6B-^2!<RBGFB!^-$"D'M\+OK#CA88=K3
M\"U9P"SJB188/EH <N.O1G\L/E[Q6[:A/@,T43;Y]U' Q7<6=(CT^TFT\) [
M?S7RU97M%9]R=D=VS]\XU7= ;19H0('[P%_:(69H9-*.@-\)U';>W>9XCP-U
MB/4@H"' E;>7<M#NKS-HI>&W!Q7S*2M*E/U#5L[V@0]H4]T  M?>5]8A#C#R
M:!] [A[*<]89Q\BBO"VDGPBIA>"IZZ'>HF=]I%80<D=0/AV;39>,VG^]<875
M<C3#\-1L*:%%T>9HK2KDGMT-3M9<>#&*9[>R3$-55U@M23,,3]66$EI4;8[6
MJD+NN=UR))^VO[G/9RPS)+7&U&(8,7AB^LBW*&D,U4_*0.Z;7;(::<M#;AZ$
M6A4K IZP[86TR&M-H$6&W!G31Y@OVV2)Z );?D#W08PC<1T"3^<.I70\(M<S
M:*7A-\"^Y)@OA$^_<K8IEV.6KQ"UW_QZD;6[(0<2GOS="^MT/^1(I,T N2GV
MI_!PB:G@G*^I^E7/?!3.BU'KY,# D[Y+,2VB.U)HN2%WO&Y81A)2"J]^0R7F
M!)F796Z /L); /!4;BVC[>AN&:_UA=SGFG(L;8EI@JM_4,A_Z_"K^;QQG]P.
M5 OE \+3O7-9+?K[\F@?0.YS&?PG1;'&O+,;G'"[)RQP\,YH*_$P?UBR:9<\
MMY=V&C:6\$)LD'\[WT7DB_R;]L?_ 5!+ 0(4 Q0    ( ):+5E9^0J"ASH@
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3!@     %  4 3P$  -NR      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
